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Overview 
 
This thesis is submitted in partial fulfilment of the requirements for the degree of 
Clinical Psychology Doctorate at the University of Birmingham. There are two volumes to the 
thesis, which illustrate research (Volume I) and clinical work (Volume II). 
 
Volume I contains a literature review, research paper, and public domain paper. The 
literature review summarises research that explored the impact of different psychological 
therapies on negative symptoms in schizophrenia and related disorders. The research paper 
describes an investigation into the negative symptoms experienced by people with 
schizophrenia or schizoaffective disorder who use cannabis, compared to those who do not. It 
is intended that both pieces of work will be submitted to ‘Schizophrenia Research’ for 
publication. The public domain paper summarises both the literature review and research 
paper. 
 
 Volume II contains five clinical practice reports (CPRs). CPR1 is a case formation 
about a 21 year old man with a learning disability, an Autistic Spectrum disorder, and who 
experiences anxiety and shows aggression. CPR2 is a service evaluation about the 
effectiveness of a multidisciplinary team referral process in a learning disability service. 
CPR3 documents a single-case experimental design that assessed the effectiveness of a 
toileting intervention with a ten year boy with secondary encopresis. CPR4 depicts a case 
study of an 81 year old man with memory loss and depression. An abstract outlining CPR5, a 
clinical presentation about a 50 year old woman with mixed anxiety and depressive disorder, 
is also included.    
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LITERATURE REVIEW 
 
 
THE IMPACT OF PSYCHOLOGICAL THERAPIES ON NEGATIVE SYMPTOMS  
OF SCHIZOPHRENIA AND RELATED DISORDERS 
THERAPIES AND NEGATIVE SYMPTOMS     
Abstract 
Negative symptoms in schizophrenia and related disorders have been associated with 
poor social functioning (e.g. Bowie, Reichenberg, Patterson, Heaton, & Harvey, 2006), longer 
hospitalisation (Pogue-Geile & Harrow, 1984), and poor medication compliance (Tattan & 
Creed, 2001). Therefore, psychological interventions have been introduced to the treatment of 
psychosis symptoms, either as an adjunct or an alternative to medication. In this review 31 
articles published in the past 11 years are described and compared in relation to their 
effectiveness at reducing negative symptoms. These interventions included Cognitive 
Behavioural Therapy, family interventions, Cognitive Remediation Therapy, and Body-
Oriented Psychological Therapy.  Although results varied across studies, the majority of the 
research suggests that all four psychological therapies are effective at reducing negative 
symptoms. Improvements were maintained for varying durations, from four weeks to five 
years. Individual Cognitive Behavioural Therapy appeared to have the most consistent 
research regarding its potential to improve negative symptoms. 
 
Keywords: negative symptoms; schizophrenia; psychosis; psychological; therapy.  
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Introduction 
Schizophrenia affects approximately one percent of the population during their 
lifespan (Jones & Meaden, in press). A diagnosis of schizophrenia requires two of the 
following symptoms to be frequently present for at least one month: negative symptoms (such 
as poverty of speech, blunted affect, or limited motivation) positive symptoms (such as 
delusions or hallucinations) or disorganised speech and behaviour (DSM-IV-TR; American 
Psychiatric Association, 2000). The DSM-IV-TR also states that functioning should be 
interrupted following symptom onset, symptoms and poor functioning are present for six 
months or more, and difficulties are not explained by pervasive developmental disorders or 
mood disorders. Other psychotic disorders include schizophreniform disorder, which occurs 
for between one and six months; schizoaffective disorder, which includes depressive or manic 
episodes; delusional disorder, which involves delusions about everyday events but other 
symptoms of schizophrenia are absent; and psychotic disorders such as brief, and substance 
induced psychotic disorders (American Psychiatric Association, 2000). 
Some researchers have proposed theories that symptoms of schizophrenia are likely to 
occur in two distinct ‘groups’, namely positive symptoms and negative symptoms (e.g. Crow, 
1980; Lewine, Fogg, & Meltzer, 1983). Others have suggested that three groups of symptoms 
can be differentiated, which they have called ‘psychotic symptoms’, ‘disorganised 
symptoms’, and ‘negative symptoms’ (Andreasen, Arndt, Alliger, Miller, & Flaum, 1995; 
Liddle, 1987). Positive symptoms are said to include experiences additional to ‘normal’ 
functioning, such as delusions, thought disorder, and hallucinations. ‘Negative symptoms’ 
have been suggested to describe deficits in daily functioning, specifically a loss of emotion 
and motivation (e.g. Birchwood, Hallett, & Preston, 1989). In DSM-IV-TR (APA, 2000), 
negative symptoms include affective flattening, ‘alogia’,  a term describing poverty of speech, 
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‘avolition’, which describes a lack of motivation to achieve goals, and ‘anhedonia’ a lack of 
pleasure in normally enjoyable activities. Crow (1980) suggested a neurochemical explanation 
of symptoms in schizophrenia.  He theorised that positive symptoms, or ‘type I syndrome’ as 
he described them, were associated with the transmission of dopamine in the brain, whereas 
the negative symptoms, or ‘type 2 syndrome’, were more likely to occur in association with 
changes in brain structure. A psychosocial theory of negative symptoms in schizophrenia 
suggests that they occur as an avoidance reaction towards problematic psychological and 
social situations, such as rejection from society. Whilst initially protective, these symptoms 
are said to be maintained as social opportunities that could increase motivation and pleasure 
are avoided, and skill retention is impeded (e.g. Strauss, Carpenter, & Barko, 1974; Strauss, 
Rakfeldt, Harding, & Lieberman, 1989). A contrasting psychoanalytical view is that negative 
symptoms stem from an inability to relate to other individuals (Meehl, 1962). Another theory, 
which combines biological and psychological perspectives, suggests that there are two types 
of negative symptoms. King (1998) suggested that ‘primary negative symptoms’ are deficits 
caused by the disorder itself, whereas ‘secondary negative symptoms’ are a consequence of 
positive symptoms, sedation, depression, or extrapyramidal side effects from antipsychotic 
medication.  
Negative symptoms appear to be more prone in some individuals with psychosis than 
others. For example, it appears that males are more likely to experience negative symptoms 
(Schultz et al., 1997) particularly blunted affect (Goldstein, Santangelo, Simpson, & Tsaung, 
1990) and emotional withdrawal (Josiassen, Roemer, Johnson, & Shagass, 1990). Individuals 
of any age may experience negative symptoms, and they may persist throughout the course of 
the illness, despite likely reductions in positive symptoms in older age (Davidson et al., 1995; 
Johnstone, Owens, Colter, & Crow, 1989; Pfohl & Winokur, 1982; Schultz et al., 1997). All 
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ethnicities researched seem to experience negative symptoms, and these do not appear to 
differ across ethnicities (Arnold, et al., 2002; Barrio et al., 2003; Dassori et al., 1998). 
 
The Impact of Negative Symptoms 
Negative symptoms have been negatively correlated with overall functioning (e.g. 
Siegel et al., 2006), social functioning (Bowie et al., 2006; Breier, Schreiber, Dyer, & Picker, 
1991; Brill et al., 2009; Hwu, Tan, Chen, & Yeh, 1995; Pogue-Geile & Harrow, 1984); 
occupational functioning (Breier et al., 1991; Brill et al., 2009; Pogue-Geile & Harrow, 1984); 
and independent functioning (Breier et al., 1991). Severe levels of negative symptoms are 
related to longer hospitalisation (Pogue-Geile & Harrow, 1984) and less medication 
compliance (Tattan & Creed, 2001), compared to those with less or no negative symptoms. If 
negative symptoms are persistent, and are associated with adverse outcomes, it seems key that 
the experiences of these symptoms are understood and effective interventions are identified to 
reduce them. 
 
Treatments for Negative Symptoms 
 National Guidelines 
The National Institute for Health and Clinical Excellence recently produced guidelines 
regarding the treatment of schizophrenia (NICE; 2009). Although recommended treatments 
were outlined, such as antipsychotics, cognitive behavioural therapy (CBT) and family 
interventions, there was a lack of interventions specifically recommended to reduce negative 
symptoms. Art therapy was suggested as a treatment option for people with negative 
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symptoms to enhance communication skills and help them understand emotions, and thus not 
specifically aiming to reduce negative symptoms.   
 
Pharmacological Interventions 
Carpenter, Heinrichs, and Alphs (1985) reviewed the effects of typical antipsychotics 
and suggested that whilst some negative symptoms reduce as medication improves positive 
symptoms; some medication can create difficulties like emotional blunting, social withdrawal 
and apathy. It has been suggested by some researchers that people who suffer from severe 
negative symptoms may benefit from a reduction (Kane, Rifkin, Woerner, & Reardon, 1982) 
or cessation of their typical antipsychotic medication (Carpenter & Heinrichs, 1983). With 
regards to atypical antipsychotics, King (1998) noted that any improvements in negative 
symptoms may be due to reductions in secondary rather than primary negative symptoms.   
As negative symptoms have been associated with non-compliance with medication 
(Tattan & Creed, 2001), this suggests that an alternative treatment is required. As 
recommended by the NICE Guidelines for Schizophrenia (NICE, 2009) the alternative or 
adjunct to pharmacological treatments should be psychological interventions. 
 
Aims of Current Literature Review 
No literature reviews focusing specifically on the effects of psychological therapies on 
negative symptoms were found. However, three systematic reviews, published in 2000, were 
found that focussed on the effects of different psychological interventions on all symptoms of 
psychosis (Psychosocial Skills Training, Heinssen, Liberman, & Kopelowicz, 2000; Family 
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psychoeducation, Dixon, Adams, & Lucksted, 2000; CBT, Garety, Fowler, & Kuipers, 2000). 
Within these reviews, they found that negative symptoms reduced following CBT (Tarrier et 
al., 1998), Psychoeducation, social skills and problem solving skills training (Halford, 
Harrison, Kalyansundaram, Moutrey, & Simpson, 1995), and family education (Mingyuan et 
al., 1993). This systematic review aims to assess the impact of psychological therapies on 
negative symptoms of psychosis. Articles published after the search dates for the previous 
three reviews were included. The review intends to assess the evidence for the effectiveness 
of different interventions, address the limitations of current literature, and further research 
will be recommended.  
 
Search Strategy 
Recent articles relating to psychological treatments for negative symptoms in 
psychosis were identified using four electronic databases, PsycInfo, Medline, EMBASE, and 
Cinahl, covering the years 1999 until March 2010. The following search terms were used: 
(affect* OR effect* OR success* OR efficac* OR outcome* OR evaluat*) AND ((psycholog* 
OR behavio* OR remediation* OR cognit* OR art* OR famil* OR psychodynamic OR 
psychoanalytic OR morita OR motivation* OR psychosocial OR psychoeducation* OR 
interperson*) adj3 (treatment* OR intervention* OR rehabilita* OR therap* OR interview*). 
OR (problem adj1 solv*). OR CBT. AND (exp "POSITIVE AND NEGATIVE 
SYMPTOMS"/ (negative adj1 symptoms). OR (anhedonia OR avolition OR alogia)) AND 
(psychos* OR schizophreni* OR "schizotypal disorder*" OR "delusional disorder*" OR 
"schizoaffective disorder*"). The search terms were chosen to encompass the key elements of 
the title of this review.  
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The search results were limited to empirical studies written in English, this produced 
265 unique articles across the four search engines. One hundred and ninety one of these were 
disregarded as they did not report the effects of a solitary therapeutic intervention for 
psychosis, 35 were eliminated as they were not empirical papers but rather reviews or 
international dissertation abstracts, and a further 11 were excluded as they did not report 
measurements of negative symptoms. Therefore 31 journal articles remained, which described 
24 studies. Two additional papers were retrieved from reference lists of ‘follow-up’ papers, 
and where the original papers had not been highlighted by the electronic search. These articles 
are detailed in Table 1. 
 
Terminology 
The term ‘Psychosis’ refers to a group of psychotic disorders (DSM-IV-TR; American 
Psychiatric Association, 2000) including schizophrenia, schizoaffective disorder, delusional 
disorder, and psychotic disorders. In this review ‘psychosis’ will be used when research 
included individuals with a variety of these disorders. However, it is recognised that negative 
symptoms may differ between these disorders. When research only included individuals with 
schizophrenia, this will be identified. 
  ‘Psychological therapies’ refers to non-pharmacological treatments that aim to 
improve outcome. Solitary psychological therapies that effect negative symptoms will be 
considered here. Therefore articles that included two therapeutic components, such as CBT 
and family psychoeducation, were not included. The psychological therapies identified during 
the electronic search as being published in the past 11 years were CBT, family interventions, 
Cognitive Remediation Therapy (CRT), and Body-Orientated Psychological Therapy (BPT). 
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Historically the main psychological intervention offered for negative symptoms have been 
behavioural approaches including token economies (e.g. Li & Wang, 1994), social skills 
training (e.g. Dobson, McDougall, Busheikin, & Aldous, 1995) and problem-solving skills 
training (e.g. Slade & Bentall, 1989). Although some of the recent research encompasses 
social skills and problem-solving strategies, no recent articles evaluating these interventions 
were found. 
       
Table 1 
Psychological Interventions for Psychosis that have Assessed Negative Symptoms.  
Study Participants Intervention Methodology Results 
CBT 
Interventions 
    
Klingberg et al., 
2009 
N=198, Outpatients. Schizophrenia with 
negative symptoms, no positive symptoms.  
Total sample: Mean age: 36.9; age at first 
hospitalisation: 24.4; 56.1% male. 
Individual Formulation-
based CBT. Focus: 
negative symptoms 
RCT. Single Blind assessment 
Design: 2 groups: 1) CBT. 20, 50 min sessions. 
over 9 months. 2) CRT (controlled for being in a 
trial and having therapy). CRT not described. 
 
Data not available currently. 
Serruya & 
Grant, 2009.  
Outpatients. Paranoid schizophrenia 
25 years old. Caucasian. Male. Duration of 
illness: 1 year approximately. 
CBT. Focus: negative 
symptoms, engagement, 
delusions.  
Case Study. Single Blind assessment 
Method: individualised CBT for 6 months/38 
sessions. 
Measures at pre, post, and at 12 mth follow-up . 
Negative symptoms reduced (but no 
statistics in article).  Reductions in alogia, 
avolition-apathy, and anhedonia-asociality 
from baseline to follow-up.  Delusions 
reduced from pre to post to follow-up. 
 
Christodoulides, 
Dudley, Brown, 
Turkington, & 
Beck, 2008. 
N=3, Outpatients. Schizophrenia. 
Age range from 16 – 60 years. Males and 
females. Duration of illness: 5-8 years. 
 
Individual CBT for 
persistent positive 
symptoms. Focus: 
symptoms, distress, 
decreasing disability, 
anxiety and depression. 
 
Case series. Data from Sensky et al (2000) RCT.  
Measures at Pre, post-treatment and follow-up.  
Case B: sig decrease in negative 
symptoms. Case A and C showed trend of 
decrease post therapy.  
Turkington et 
al., 2008. 
N=59, Outpatients. Schizophrenia with 
persistent positive symptoms. 
31 CBT followed-up, 28 BF followed up.  
No significant difference at baseline. 
Individual CBT for 
persistent positive 
symptoms. Focus: 
symptoms, distress, 
decreasing disability, 
anxiety and depression. 
RCT. 5-year Follow-up from Sensky et al (2000) 
study.  
Participants attended 20 sessions of CBT over 9 
months, or befriending for 9 months.  
Measures at pre, post, 18 mth, 5 yr follow-up. 
CBT Vs Befriending: CBT significant 
decrease: negative symptoms and overall 
symptoms. No difference between groups: 
positive symptoms, depression, number of 
days hopitalised. 
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Amell & 
Llandrich, 2008. 
N=57, Outpatients. Schizophrenia 
SSTP group: Mean age: 27.7 years (s.d 
6.52).  60% male. Duration of illness: 8.25 
years (s.d. 6.05).  
Control: Mean age: 27.8years (s.d.5.79). 
63.6% male. Duration of illness: 8.36 years 
(s.d.5.34 years). 
No sig group differences in demographics.  
Social skills training 
programme in groups.  
Quasi effectiveness study. Random assignment 
to groups. 
2 groups: 1) social skills training group (SSTP) 
(1.5 hours once per week for 20 weeks) and 
antipsychotic medication; 2) antipsychotics 
medication only. 
Measurements at baseline, post-therapy, and 6 
month follow-up (after therapy was complete). 
Pre Vs post: SSTP: sig decrease: total 
negative symptoms, emotional withdrawal, 
social withdrawal, lack of spontaneity, 
anxiety, poor attention, preoccupation, 
active social avoidance, and volition. 
Increased social role.  
Post Vs Follow-up: SSTP: sig increases in 
blunted effect, stereotyped thinking, and 
volition disturbance. Roles maintained. 
 
Turkington et 
al., 2006. 
N=336, Inpatient and Outpatients. 
Schizophrenia. 
Participants recruited: mostly male, white 
(specific values not reported). 
No significant group differences at baseline. 
Technique based CBT. 
Focus: managing positive 
symptoms and negative 
symptoms, medication 
compliance, beliefs about 
self and others, and relapse 
prevention.  
Quasi effectiveness study 
2 groups: 1) CBT group (each person had 6 
sessions over 2-3 months plus 3 sessions for 
carer if patient agreed); 2) Treatment as usual 
(TAU) 
Measures at baseline, post and 12 mth follow-up. 
 
Follow-up: CBT: sig increase: insight, sig 
decrease: total negative symptoms, 
apathy, avolition, and asociality, number of 
relapses, time in hospital, compared to 
TAU. No difference: psychotic symptoms.  
 
Granholm, 
Auslander, 
Gottlieb, 
McQuaid, & 
McClure, 2006. 
N=32 (CBT group from 2005 study), 
Outpatients. Schizophrenia or schizoaffective 
disorder.  
Mean age: 54.2 years (s.d 7.0) range 42-74.  
N=32: Caucasian (81%). Male (75%). Mean 
duration of illness: 29.3 years; (s.d=9.2).  
Cognitive-behavioural social 
skills training group 
(CBSST) 
RCT 
Described CBT group (from an original CBT, TAU 
comparison in 2005). CBT: 24, 2-hour group 
sessions (modules repeated twice to compensate 
for cognitive impairment) 
Measures at baseline and post- group. 
 
CBSST: increased: cognitive insight - 
correlated with greater reduction in 
positive, negative, total symptoms, 
participation.  
Greater participation – correlated with 
greater reduc. in total negative symptoms.  
Barrowclough 
et al., 2006.  
N=113, Outpatients. Schizophrenia or 
schizoaffective disorder with persistent 
positive symptoms.  
Total sample: 82 (72.6%) male; Mean age: 
38.83 years (s.d.8.6); Mean illness. Duration 
was 13.67 years (s.d.7.99). 
Group CBT. Focus: 
delusional and 
hallucinations.  
RCT 
Compared 2 groups: 1) CBT group and TAU (18, 
2-hr sessions for 6 months); 2) TAU.  
Measurements taken at baseline, 6 months 
(post); and 12 months (follow-up) 
CBT Vs TAU: no difference: positive, 
negative (trend to sig), global, total 
symptoms, relapse, functioning at post or 
follow-up. CBT: sig reductions: feelings of 
hopelessness, low self-esteem at follow-
up. 
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Knight, Wykes, 
& Hayward, 
2006. 
 
N=21, Inpatients and Outpatients. 
Schizophrenia spectrum disorders.  
Mean age: 39.32 (s.d. 8.785); 11 males; 
ethnicity: 9 white, 8 black, 1 south African, 3 
other. Mean age of onset: 25.89 (s.d. 7.661). 
 
CBT group. Focus: stigma 
and self-esteem, and 
maladaptive coping 
strategies.  
 
Quasi effectiveness study 
Waitlist control. CBT: one hour per week. 
Measures at baseline (week 0) pre (week 6) post 
(week 12) and follow-up (week 18). 
 
Control phase: no difference in symptoms. 
Baseline Vs Post: sig improvements in 
self-esteem, positive symptoms, negative 
symptoms, depression. Follow-up: remain 
sig improved: positive, negative, general 
symptoms. 
 
Warman, Grant, 
Sullivan, Caroff, 
& Beck, 2005. 
N=6. Unclear setting. Paranoid 
schizophrenia and schizoaffective disorder.  
Mean age: 48.83 years (s.d. 5.3) (range 44-
59). 6 (100%) males; mean age of first 
episode: 21.4 years (s.d. 1.5). 
Individual and group CBT 
for schizophrenia; 
depression; anxiety. 
Quasi effectiveness study. 
Single blind assessment at follow up. 
No control. All 6 had therapy. Therapy alternated 
between group and individual sessions weekly 
(24 weeks). 
Measures at baseline, post, 11 mth follow-up. 
Baseline to post: sig decrease: negative, 
positive symptoms, delusions, anxiety and 
depression. No change: hallucinations.  
Baseline to follow-up: sig decrease: 
positive symptoms. No difference: 
negative symptoms, delusions, 
depression, anxiety and hopelessness. 
 
Startup, 
Jackson, 
Evans, & 
Bendix, 2005.  
 
  
N=60, Acute Inpatients. Schizophrenia 
spectrum disorder.  
No demographic data in article.  
No significant difference between groups. 
Individual CBT: formulation 
based.  
RCT 
Compared two groups: 1) TAU (pharmacology, 
inpatient, and community nursing care).  2) TAU 
and CBT. 
Measures at baseline, and 6, 12,  24months 
CBT Vs TAU: CBT sig reductions: 
negative symptoms at post and 24 month 
follow-up. Positive symptoms at post. Sig 
increases: social functioning at post and 
follow-up. 
Temple, & Ho, 
2005. 
N=19. Outpatients. Schizophrenia with 
persistent positive symptoms.  
CBT (n=10): Mean age: 29.8 (s.d. 9.16); 5 
males; age of onset: 21 (s.d. 7.2). 
TAU (n=9): mean age: 35.9 (s.d. 5.6); 5 
males; age of onset: 24.2 (s.d. 8.3). 
Individual CBT. Focus: 
symptoms, daily adaptive 
functioning. 
Quasi effectiveness study 
Case controlled 
2 groups: 1) CBT (up to 20 individual sessions); 
2) TAU. 
Measures at baseline and six months. 
CBT Vs TAU: CBT sig improvement: 
psychosocial functioning, overall 
symptoms, delusions, clinical global 
impression of improvement, and global 
assessment scale at 6 months. Trend 
towards significance in reduced negative 
symptoms (p<0.06)  
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Gumley et al., 
2003. 
N=144. Outpatients. Schizophrenia or 
‘related disorders’ with relapse in previous 2 
years. 
CBT (n=72): mean age: 35.8 (s.d. 9.6); 54 
(75%) males; dur of illness: 113 mths (s.d. 
81); CBT had lower self-esteem. 
TAU (n=72): mean age: 36.7 (s.d. 10.1); 51 
(70.8%) males; dur of illness: 114 mths (s.d. 
84).  
 
Individual CBT. Focus: 
relapse education and 
prevention.  
RCT 
2 groups: 1) CBT and TAU (5 session 
engagement, and intensive targeted phase twice 
per week when prodromal signs/early signs 
detected, CBT terminated when early signs at 
baseline level); 2) TAU (CMHT clients). 
Measurements at baseline, 12, 26, 52 weeks. 
Early signs every 2 weeks. 
CBT Vs TAU: CBT sig improvements: 
positive, negative, global symptoms, 
independent functioning, prosocial 
activities. Less people relapsed.  
Rector, 
Seeman, & 
Segal, 2003. 
N=42, Outpatients. Schizophrenia or 
schizoaffective disorder with persistent 
positive and negative symptoms. 
CBT and ETAU (n=24): mean age 37.5 
(s.d.8.3); 62% male;  age first diagnosis: 
25.3 (s.d. 6.4);  
ETAU (n=18):age 41.2 (s.d 10.9); 28% male;  
age first diagnosis: 23.2 (s.d. 7.0);  
No significant group differences at baseline.  
 
Individual CBT. Focus: 
engagement, normalising, 
improving positive 
symptoms and negative 
symptoms, anxiety, 
depression, relapse 
prevention.   
RCT 
Single blind assessors 
2 groups (randomly assigned): 1) CBT (20 
sessions of individual CBT over 6 months) and 
ETAU (enriched standard treatment); 2) ETAU 
only.  
Measurements taken at pre-, post-, and 6 month 
follow-up (6 months from post measures; 12 
months from pre measures) 
CBT and ETAU sig reduced: negative, 
positive symptoms to post. Trend towards 
greater improvement in CBT. CBT sig 
greater reduction at 6 month follow-up: 
negative symptoms. 
Johns, 
Sellwood, 
McGovern, & 
Haddock, 2002. 
N=4, Clinical setting unclear. Schizophrenia 
with persistent negative symptoms, no 
positive symptoms.   
Median age: 33 years (range 29-45); gender: 
100% male; median duration of illness: 6 
years (range 5-20); 2: medication reduced. 
Group CBT for negative 
symptoms particularly 
targeting avolition/apathy. 
Quasi effectiveness study 
Baseline control for 5-7 weeks. 
CBT group (16 sessions, 1.5-2hours each). 
Measurements taken at pre-baseline, pre-
intervention, and post-intervention.  
Baseline phase: No sig change in 
symptoms, depression, side effects,  
Post: sig reduction in avolition/apathy. 
Trend towards sig reduction in total 
negative symptoms.  
 
 
Tarrier et al., 
2001. 
N=72. Outpatients. Schizophrenia, 
schizoaffective or delusional disorder.  
Individual CBT focusing on 
increasing coping strategies 
for recurring positive 
RCT 
3 groups: 1) CBT + routine care (20 sessions, 2-
CBT Vs Supportive Counselling and TAU: 
CBT sig improvements: hallucinations, 
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CBT (n=24): mean age: 42.29 years; 15 
males (63%); duration of illness: 15.13 years. 
Supportive counselling (n=21): mean age: 
39.14 yrs: 15 males (71%); duration: 15.43 
yrs. 
Routine care (n=27). Age: 37.19 yrs; gender: 
24 males (89%): duration: 11.85 yrs.   
No significant group differences at baseline. 
 
symptoms; problem solving 
to increase functioning; 
relapse prevention. 
weekly over 10 weeks) then after post-treatment 
4 booster sessions, 1 per month; 
2) Supportive counselling + routine care (same 
session pattern); 3)TAU. 
Treatment took 3 months. 
Measures at pre and post therapy. 
delusions. 
All groups: sig decrease in negative 
symptoms. Trend towards greater 
reduction in CBT for negative symptoms, 
alogia. 
Sensky et al., 
2000. 
N=90, Outpatients. Schizophrenia with 
persistent positive symptoms.  
CBT group (n=46): mean age 39 (range 35-
42); 31 males (67%); ethnicity: 40 whites, 6 
non-whites; duration of illness: 14 years (12-
17 yrs). 
Befriending group (n=44): mean age: 40 
years (35-45); 22 males (50%); ethnicity: 40 
whites, 4 non-whites; duration of illness: 15 
years (11-18 yrs). Sig more females in 
befriending group then CBT group. Men: 
higher negative symptoms and global 
psychopathology at baseline. 
 
Individual CBT for 
persistent positive 
symptoms. Focus: 
understanding symptoms; 
decreasing distress; 
decreasing disability, 
anxiety depression, 
negative symptoms. 
RCT 
Single blind assessment 
2 groups (randomly assigned): 1) CBT; 2)) 
befriending. 
Both therapies: 9 months. Average number of 
sessions was 19. Therapy was conducted by 2 
experienced nurses.  
Measures at baseline, post-therapy, and 9-month 
follow-up. 
CBT Vs Befriending at post: Both sig 
improved: global psychopathology, 
negative symptoms, depression.  
Follow-up: CBT sig greater improvements: 
global psychopathology, negative 
symptoms; and depression. 
Tarrier et al., 
1999. 
N=70, Outpatients. Schizophrenia, 
schizoaffective or delusional disorder with 
persistent positive symptoms. 
Whole sample demographics: Mean age: 
39.4 years (s.d. 10.9 years); Gender: 74% 
male; mean duration of illness: 14.2 years 
(s.d. 9.9 years).  
Individual CBT. Focus: 
coping strategies for 
reducing positive 
symptoms; problem solving 
to increase functioning; 
relapse prevention.  
Quasi effectiveness study 
Single blind assessment 
3 groups (stratified for age and symptom 
severity): 1) CBT + TAU (20 sessions, 2-weekly 
over 10 weeks plus 4 booster session); 2) 
Supportive counselling + TAU (same session 
pattern as CBT); 3) TAU  
CBT Vs TAU : CBT sig improved: positive 
symptoms, negative symptoms at post. 
Trend towards sig in negative symptoms at 
follow-up. 
Supportive counselling: sig decrease: 
negative symptoms post and follow-up. 
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Measures at pre , post, 12 mths post-treatment (8 
months after booster sessions finished). 
Family 
Interventions 
    
Bradley et al., 
2006 
N=50, Outpatients. Schizophrenia, 
schizoaffective disorder and 
schizophreniform disorder.  
Multiple-family grp (n=25): mean age: 33.6 
yrs (s.d. 6.68); 28% males; English speaking: 
13 (52%). 
Control grp (n=25):age: 34 yrs (s.d. 9.6); 
32% males; English speaking: 17 (68%). 
 
Cognitive-behavioural multi-
family group treatment,. 
Focus: problem-solving. 
Intervention for one year. 
Quasi effectiveness studies 
2 groups in each culture group: 1) multi-family 
group treatment) (26 sessions over 12 months 
and 3 for family members and 2 half-day 
psychoeducation sessions); 2) control (case 
management/TAU).   
Measures pre, post, and 18-month follow-up. 
Family Intervention Vs TAU: Both groups: 
no change in negative symptoms post or 
follow-up. Family intervention: 
improvements: thought disturbance and 
disorganisation at post, relapse rates at 
post and follow-up. 
 
Dyck et al., 
2000  
N=63, Outpatients. Schizophrenia or 
schizoaffective.  
Multi-family group (n=32): Age: 33 (s.d. 8 
years). 23 (72%) male. 30 (94%) white. 
Duration of illness: 11years (s.d 8). 
Standard care (n=31): Age: 33 (s.d. 10 
years). 23 (73%) male. 30 (97%) white. 
Duration of illness: 10years (s.d. 8) 
No significant group differences at baseline. 
48% met criteria for substance abuse. 
 
Psychoeducation in 
multiple-family groups. 
Focus: problem solving, 
engage family, increase 
social networks, education 
about schizophrenia. 
Intervention for 2 years. 
Quasi effectiveness study. 
Single blind assessment. 
2 groups randomly assigned (stratified for 
antipsychotics): 1) Multi-family group 
psychoeducation + standard. 2) TAU (incl 
rehabilitative and supported employment for 
some) 
Negative symptoms assessed once per month for 
12 months (first year of 2-year intervention.) 
Family intervention Vs TAU: Family 
Intervention sig reduced: total negative 
symptoms, avolition, flattened affect, 
alogia, asociality, but not inattention. 
  
CRT 
Interventions 
    
Eack et al., 
2009 
N=58. Setting unclear. Schizophrenia or 
schizoaffective disorder, with social and 
cognitive disabilities. 
Total sample: mean age: 25.92 +/- 6.31 
Individual and group CRT. 
Computerised CRT focused 
on attention, memory, 
problem-solving, and social-
RCT 
Design: 2 groups: 1) CRT. 60 (one-hour 
computerised CRT sessions, one per week, and 
45 1.5-hour social-cognitive group sessions, once 
CRT Vs enriched supportive therapy: CRT 
sig reduced: negative symptoms, anxiety, 
depression, neurocognitive functioning at 
post and follow-up.  
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years; 69% male; Ethnicity: 69% Caucasian, 
19% African-American, 10% Asian, average 
duration of illness: 3.19 years +/- 2.24 years. 
No significant differences at baseline.  
 
cognitive group sessions. 
Focus: extracting important 
parts of social interactions. 
per week). 2) ‘Enriched Supportive Therapy’.  
Number and length of sessions not described, but 
interventions 1 and 2 not matched for number of 
sessions.  
Wykes et al., 
2009 
N=85, Outpatients. Schizophrenia with social 
functioning problems.  
Mean Age: 36 years; contact with psychiatric 
services 10+ years: 52% (n=44); 73% male. 
No sig group differences at baseline except 
higher symptoms in CRT. 
Individual Cognitive 
remediation therapy. Focus: 
memory, cognitive flexibility 
and planning 
RCT 
Design: 2 groups: 1) CRT and TAU (40 face-to-
face one hour session including paper and pencil 
tasks and practice cognitive skills). 2) TAU.  
 
 
Younger (17- 39 years): Sig reduction in 
negative symptoms following CRT. Sig 
improvement in memory and planning 
post, and improved cognitive flexibility at 
follow-up. 
Older (40-65 years): No sig improvements 
in negative symptoms, planning, cognitive 
flexibility, post CRT. Improved memory. 
 
Vauth et al., 
2005. 
N=138, Inpatients. Schizophrenia.  
Total sample: Mean age= 28.8 years 
(s.d.7.1); 64.5% male; Mean age of illness 
onset was 22.8 years (s.d. 5.6); Mean 
duration of illness=6.6 years (s.d. 5.5).  
No sig group differences at baseline. 
 
CAST: Group Computer-
assisted cognitive strategy 
training. Focus: selective 
attention, verbal memory, 
planning.  
TSSN: Training of self 
management skills for 
negative symptoms  
 
RCT 
Compared 3 groups: 1) CAST and vocational 
training; 2) TSSN and vocational training; 3) 
vocational training (control). 
Measures taken at baseline/intake, and post 
intervention (8 weeks later). 
TSSN: No sig improvement to negative 
symptoms vs groups or time. No cognitive 
improvements. 
CAST: Sig improvements: verbal memory, 
negative symptoms, trend towards sig: 
attention vs control. No sig difference in 
planning ability.  
Bark et al., 
2003. 
N=54, Inpatients. Schizophrenia and 
schizoaffective disorder.  
CRT (n=36): age: 35 (s.d. 7.07); 24 male; 
age at first hospitalisation: 20.57 (s.d. 4.16). 
TAU (n=18): age: 38.55; 8 males; mean age 
of first hospitalisation: 23 (s.d. 7.27). No 
differences at baseline. 
CRT (unclear whether 
individual or group). 
Quasi effectiveness study 
Single blind assessment 
Design: 2 groups, 1) 10-sessions CRT (2 types, 
problem-solving CRT and memory CRT); 2) TAU 
Measures at pre, post, and 4 week follow-up. 
CRT Vs TAU: CRT sig improved: positive, 
negative, general symptoms, depression. 
Change was maintained at 4 week follow-
up. 
Memory CRT Vs Problem-Solving CRT: 
Memory CRT sig improved negative 
symptoms. 
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Bellucci, 
Glaberman, & 
Haslam, 2003. 
N=34, Outpatients. Schizophrenia or 
schizoaffective disorder without 
hallucinations or prominent thought disorder. 
Total sample: 16 (47.1%) male; mean age: 
42.0; yrs since first hospitalization: 16.6, yrs 
since first contact with program: 4.9.  
 
Individual Computer-
assisted cognitive 
rehabilitation (CACR) 
therapy, focus: attention; 
visual/motor; conceptual; 
numeric memory skills. 
Quasi effectiveness study 
Compared 2 groups (randomly assigned): 1) 
computer-assisted CRT group (16, 30-minute 
sessions over 8 weeks); 2) wait-list control.  
Measurements taken at pre and post-therapy. 
CACR Vs control: CACR sig reduced: total 
negative symptoms, anhedonia, flattened 
affect, verbal learning memory, 
attention/concentration. 
Penadés et al., 
2002. 
N=8, Outpatients. Schizophrenia with 
negative symptoms and cognitive 
impairments. 
Total sample: 6 males; mean age: 32 years 
(s.d. 10.4); mean duration of illness: 11.4 
years (s.d. 5.5). 
Neuropsychological 
rehabilitation. Focus: 
cognitive differentiation and 
social perception, including 
attentional skills, 
conceptualisation concepts. 
Quasi effectiveness study 
24 sessions of rehabilitation over 12 weeks 
(45mins – 1 hour each). 
SPECT scan and neuropsychological tests pre 
and post therapy. 
Post: sig reduced: negative symptoms, 
verbal memory, associative learning, 
abstraction, executive functioning. No sig 
change: positive, general symptoms. 
 
BPT 
Interventions 
    
Röhricht, 
Papadopoulos, 
Suzuki, & 
Priebe, 2009. 
N=24, Outpatients. Schizophrenia with 
persistent negative symptoms.  
Mean age: 38.8 years (s.d. 9.3); 50% males; 
mean duration of illness: 12.1 years (s.d. 
10.5); mean number of hospitalisations: 3.7 
(s.d. 2.8). 
Group BPT. Focus: improve 
body image, egopathology 
symptoms and negative 
symptoms. 
RCT, data from BPT group only. 
Single blind assessment. 
BPT therapy conducted: 20 sessions, 90 minutes. 
Pre and post therapy measures. 
 
Post: sig improvements: negative 
symptoms, ego-pathology subscales 
‘body’, ‘activity’, ‘consistency’, & 
‘demarcation’. No assoc, between ego-
pathology and negative symptom. 
Increased body demarcation at baseline 
predicted negative symptom change. 
 
Röhricht & 
Priebe, 2006. 
N=45. Outpatients. Schizophrenia with 
persistent negative symptoms 
BPT (n=24): mean age: 38.8 yrs (s.d. 9.3); 
50% male; dur of illness: 12.1 yrs (s.d.10.5). 
Supportive Counselling (n=21): age: 37.7yrs 
(s.d. 9.5); 52% male: dur  of illness:10.8 
years (s.d. 7.3); No sig group differences at 
baseline.  
Group BPT. Focus: refocus 
cog and emotional 
awareness; stimulate 
activity, and emotional 
responsiveness;  modify 
self-perception; address 
boundary loss; somatic 
depersonalisation; and body 
schema disturbance.  
RCT 
Single blind assessment 
2 groups: 1) BPT; 2) supportive counselling. Both 
groups: max. 20 group sessions, 10 weeks, 60-
90 minutes. Significant difference on number of 
sessions: BPT mean: 11.3 sessions (s.d. 6.0); 
Supportive counselling mean: 4.5 sessions (s.d. 
4.8). Measures at baseline, post, 4 mth follow-up.  
BPT Vs supportive counselling: BPT sig 
reduced: total negative symptoms, blunted 
affect, motor retardation at post and follow-
up, and after controlling medication and 
side effects. No change: positive, general 
symptoms, quality of life. No sig difference 
between groups on satisfaction or 
therapeutic relationships.  
THERAPIES AND NEGATIVE SYMPTOMS     
Cognitive Behavioural Therapy 
CBT was first described as being used to relieve psychosis symptoms, specifically 
delusions, in 1952 (Beck, 2002). Since this time, CBT has been adapted and applied to several 
symptoms and difficulties in psychosis (Dickerson, 2000; Jones, Cormac, Silveira da Mota 
Neto, & Campbell, 2004; Rector & Beck, 2001). Kingdon & Turkington (1994) suggested the 
aim of CBT for psychosis is for individuals to understand symptoms as being due to internal 
‘normal experiences’. Turkington, Dudley, Warman, and Beck (2004) suggested CBT for 
schizophrenia could also improve trust, coping skills, and unhelpful responses to symptoms. 
Birchwood and Trower (2006) suggested CBT for psychosis should aim to prevent relapse, 
reduce distress, anxiety, depression, and improve self esteem, in individuals experiencing 
psychotic symptoms, or those at risk of developing psychosis. The NICE guidelines for 
schizophrenia (NICE, 2009) advise that CBT is provided to all, although there is no 
suggestion that it should focus specifically on reducing negative symptoms.  
Fifteen studies, and nineteen articles, described the effectiveness of CBT at improving 
negative symptoms.   
 
 CBT focusing on reducing symptoms 
Two studies aimed primarily to reduce negative symptoms (Johns, Sellwood, 
McGovern, & Haddock, 2002; Klingberg et al, 2009). Klingberg and colleagues’ (2009) 
randomised controlled trial (RCT) has only recently been completed and data was unavailable 
at the time of this review.  Johns and colleagues (2002) conducted group-based CBT targeting 
avolition and apathy within a routine clinical setting, although it was unclear whether 
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participants were inpatients or outpatients. The intervention achieved the aim of significantly 
reducing avolition/apathy. There was also a trend towards a significant reduction in negative 
symptoms overall, as measured on the Scale of the Assessment of Negative Symptoms 
(SANS; Andreasen, 1984). Unfortunately the sample was small. Also two individuals had 
reductions in medication during the intervention, and therefore this may be a confounding 
variable.  Johns and colleagues research did however suggest that CBT in a clinical setting 
holds promise in being able to reduce avolition in a group of males with schizophrenia, when 
compared to no intervention. 
The three studies that focused on altering positive symptoms were RCTs 
(Barrowclough et al., 2006; Sensky et al., 2000; Tarrier et al., 2001). Sensky and colleagues 
(2000) conducted an RCT comparing individual CBT and individual ‘Befriending’ sessions. 
As the sample had persistent positive symptoms, CBT focused primarily on reducing these, 
but also incorporated interventions for negative symptoms, anxiety and depression if required. 
Both CBT and Befriending showed significant improvements in negative symptoms, positive 
symptoms and depression post therapy. There was no significant statistical difference between 
CBT and Befriending, which suggests that both interventions were equally as effective at 
reducing both positive and negative symptoms, and depression. Nine months post therapy, the 
Befriending condition showed elevated positive and negative symptoms, whilst the CBT 
condition continued to show reductions in these. In a five-year follow-up of 59 individuals 
from this study, the CBT condition showed significant improvements in negative symptoms 
compared to the Befriending group, suggesting that the effects of CBT on negative symptoms 
are more durable than Befriending. Positive symptoms and depression did not differ between 
groups at this time (Turkington et al, 2008). The authors suggested that certain techniques 
such as graded activity scheduling, recording thoughts, mastery and pleasure, may have 
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activated the prefrontal cortex. They also suggested negative symptoms may remain low 
following CBT as perceived stigma may have reduced and consequently social interactions 
may have increased. Following random assignment, there were demographic differences 
between interventions. The Befriending condition had more females than the CBT condition. 
Consistent with gender trends in the literature (Goldstein et al., 1990; Josiassen et al., 1990; 
Schultz et al., 1997), males in this study had significantly more severe negative symptoms 
than females before therapy. CBT therefore included more individuals with more severe 
negative symptoms than Befriending at baseline. Yet these symptoms improved to similar 
levels in both groups following therapy, suggesting CBT is effective even when negative 
symptoms are quite severe. Due to the lack of a control group it cannot be concluded that 
improvements would not have occurred without any psychological intervention, and does not 
refute the possibility of spontaneous recovery or improvements being due to medication. 
However, three individuals not taking medication whilst attending CBT in the RCT also 
showed improvements in symptomatology, and thus the improvements were attributed to 
CBT (Christodoulides, Dudley, Brown, Turkington, & Beck, 2008). 
In Tarrier and colleagues’ (2001) RCT, there was a group that received no therapeutic 
intervention. They found that their individual CBT intervention, ‘supportive counselling’ 
condition and ‘treatment as usual’ condition all showed significant reductions in negative 
symptoms following intervention. There was a trend towards significantly greater 
improvements in negative symptoms following CBT, compared to supportive counselling and 
treatment as usual. All groups were comparable in terms of demographic variables, and 
therefore it is likely that this difference was due to treatment variables. The evidence from the 
Tarrier studies (Tarrier et al., 1999; Tarrier et al., 2001) adds to Sensky and colleagues’ 
(2000) finding that CBT focusing on reducing persistent positive symptoms is effective at 
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reducing negative symptoms. However, the two CBT interventions are not comparable. 
Sensky and colleagues focused on positive and negative symptoms and depression and 
anxiety, whilst Tarrier and colleagues focused on coping strategies to deal with positive 
symptoms, and reducing relapse rates. Although participants in both studies had similar 
durations of illness, and mean age, there were more males in Tarrier and colleague’s control 
conditions, and included people with schizophrenia, schizoaffective and delusion disorders, 
whilst Sensky and colleagues’ sample had schizophrenia.  
Barrowclough and colleagues (2006) compared group-based CBT to no 
psychotherapeutic intervention. Similar to Tarrier and colleagues (2001), this intervention 
focused on coping with positive symptoms. Conversely to Sensky and colleagues (2000) and 
Tarrier and colleagues, Barrowclough and colleagues failed to find a significant improvement 
in negative or positive symptoms immediately after CBT, or 12 months later. The CBT 
condition showed a trend towards significant reductions in negative symptoms 12 months 
post-intervention.  
Barrowclough and colleagues’ (2006) CBT condition had similar proportions of 
males, average ages and duration of illness, and diagnosis to Tarrier and colleagues’ (2001) 
CBT intervention. However, Barrowclough and colleagues’ intervention was provided in 
group format. Perhaps the one-to-one contact in Tarrier and colleagues and Sensky and 
colleagues’ (2000) studies was an element of therapy that improved negative symptoms. This 
hypothesis is supported by the significant improvements after individual supportive 
counselling and befriending. There was however significant improvements in routine care 
with no additional one-to-one intervention (Tarrier et al., 2001). This improvement was not 
replicated in another study (Barrowclough et al., 2006). 
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Similarly to the aforementioned RCT (Barrowclough et al., 2006) Temple and Ho 
(2005) found no significant improvement in negative symptoms after CBT was provided for 
people with schizophrenia and who had persistent positive symptoms in a routine clinical 
setting. Again, like Barrowclough and colleagues (2006), a trend towards significance was 
found. Temple and Ho’s CBT was delivered on an individual basis. The intervention did show 
significant improvements in overall symptoms, delusions, and psychosocial functioning. The 
study sample was considerably small. Temple and Ho’s CBT focused on reducing symptoms 
and improving adaptive functioning. Individual CBT has been found effective at reducing 
negative symptoms when the primary target of the intervention was to reduce positive 
symptoms only (Sensky et al., 2000; Tarrier et al., 2001). 
A RCT conducted by Startup, Jackson, Evans, and Bendix (2005) studied the 
effectiveness of formulation-based CBT for individuals experiencing a variety of symptoms 
of psychosis and who were acutely unwell. They found that negative symptoms, positive 
symptoms, and social functioning significantly reduced after CBT compared to individuals 
receiving inpatient care only. When assessed two years later, the improvements in negative 
symptoms continued further, and social functioning improvements remained. These results 
indicate that individually tailored CBT improved negative symptoms in inpatients initially, 
and over time. Another RCT, conducted by Rector, Seeman, & Segal (2003), assessed the 
impact of manualised CBT, where specific modules were selected to alleviate different 
psychosis symptoms as required. Both the CBT condition and control group received 
‘enhanced treatment as usual’ (ETAU) comprising of psychiatric reviews, psychoeducation 
groups, home-based outreach services, and access to occupational therapies. Both the CBT 
condition and ETAU condition led to significant reductions in negative and positive 
symptoms. Although there were no significant differences between conditions following 
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treatment, the CBT group’s negative symptoms decreased further six months following 
treatment, and the ETAU group’s did not, producing a significant difference at follow-up.   
These findings suggest that, similarly to Startup and colleagues’ intervention, the effects of 
individual CBT are durable and may even improve beyond the sessions. This may perhaps be 
due to CBT techniques being applied in daily living situations. 
In a routine clinical setting, a case study showed that alogia, avolition/apathy, and 
anhedonia, were reduced following CBT that initially focused on negative symptoms and 
engagement, then delusions (Serruya & Grant, 2009). Although clinically encouraging, no 
statistical analysis was conducted and, therefore, it is difficult to compare the results to other 
studies.  
Turkington and colleagues (2006) evaluated technique-based individual CBT for 
schizophrenia, and therefore the mental health nurses conducting the therapy used an array of 
CBT techniques to treat presenting difficulties the participants had, rather than the 
intervention being formulation-driven (Startup et al 2005). CBT aimed to manage positive 
and negative symptoms, whilst improving medication compliance, beliefs about themselves 
and others, and preventing relapse. Twelve months following therapy, CBT showed 
significant improvements in negative symptoms and insight, compared to a ‘usual treatment’. 
Positive symptoms did not significantly differ between conditions at follow-up. Unfortunately 
negative symptoms, and therefore any post-intervention changes, were not reported in the 
original publication (Turkington, Kingdon, & Turner, 2002). Additional to the individual 
therapy for people with schizophrenia, their main carers were given three sessions of CBT to 
aid their understanding of the intervention. This additional support beyond the sessions may 
have affected the outcome, and therefore conclusions cannot be made about the individual 
CBT.  
23 
 
THERAPIES AND NEGATIVE SYMPTOMS     
Warman, Grant, Sullivan, Caroff, and Beck’s (2005) study in a clinical setting 
combined individual and group-based CBT by alternating formats weekly. Similarly to 
Sensky and colleagues (2000), this CBT addressed psychosis symptoms, anxiety and 
depression. The small sample showed significant reductions in total negative and positive 
symptoms, although hallucinations did not significantly reduce.  Depression and anxiety also 
decreased significantly. However, the improvements in negative symptoms were lost at an 
eleven-month follow-up assessment. This may have been due to the sample size, or using a 
group format. The lack of a control group makes it difficult to consider what changes were 
due to CBT or other environmental, biological, or psychiatric treatment factors. None-the-less 
the findings suggest that when individual and group CBT is used in a clinical setting it can 
reduce negative symptoms in the short-term.  
 
 CBT focusing on daily functioning 
Two studies evaluated group-based CBT for improving social skills through 
communication and problem-solving training (Amell & Llandrich, 2008; Granholm et al., 
2005). The former study significantly reduced negative symptoms, whereas the latter did not 
(Granholm, Auslander, Gottlieb, McQuaid, & McClure, 2006). Interestingly, the participants 
in the Amell and Llandrich’s (2008) trial had four less sessions than Granholm and 
colleagues’ (2005) sample. The CBT sample in Granholm and colleagues’ study were much 
older (54.5 years compared to 27.7 years), and consequently the length of illness was longer 
(26.4 years compared to 8.25 years), which may suggest that CBT for social skills may be 
more effective if applied earlier in the illness or with younger individuals. Individuals with 
schizoaffective disorder were included in Granholm and colleagues’ (2005) sample, which 
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may account for varying results between the two studies. Granholm and colleagues (2006) 
found that in their sample increased cognitive insight following CBT was significantly 
associated with reductions in negative and positive symptoms, but not with improvements in 
psychosocial functioning or depression. Greater participation in sessions was significantly 
correlated with negative and positive symptom improvements.  
Gumley and colleagues’ (2003) RCT explored the impact of individual CBT in 
reducing relapse. This intervention was unique because, following some engagement sessions, 
it was initiated when relapse was indicated, and terminated when the risk of relapse 
decreased. Following CBT, there was a significant reduction in negative and positive 
symptoms, and hospital admissions, compared to ‘treatment as usual’. Unfortunately there 
was a lack of comparable interventions that were initiated at the early signs of relapse. 
However, Tarrier and colleagues (2001) also achieved reductions in negative symptoms when 
their CBT aimed to reduce relapse rates alongside positive symptoms. It can be concluded 
from Gumley and colleagues’ research that CBT was more effective at reducing negative 
symptoms in the time preceding potential relapses than no intervention. 
Knight, Wykes, and Hayward (2006) investigated the effectiveness of group-based 
CBT that aimed to improve self-esteem, coping skills, and self-efficacy. The waiting list 
control design showed no significant changes in negative or positive symptoms across the 
baseline period, but demonstrated significant improvements in negative and positive 
symptoms, depression and self esteem after CBT. Whilst these results are encouraging, this 
group intervention has only been proven successful for a small sample of inpatients and 
outpatients, and therefore replication of this study on a greater scale is required.  
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Summary for CBT Interventions 
Nine out of 14 studies that provided outcome data showed CBT effectively reduced 
overall negative symptoms. Although Amell and Llandrich (2008) did not measure overall 
negative symptoms, they did find significant reductions in emotional withdrawal, social 
withdrawal and lack of spontaneity. Perhaps the findings of Johns and colleagues (2002) were 
an anomaly, as whilst they found significant reductions in avolition/apathy, which they were 
targeting, overall negative symptoms did not significantly reduce. The sample was extremely 
small (n=4), and therefore, may not represent the potential of the intervention or population.   
Only three studies found that no negative symptoms reduced significantly following 
CBT (Barrowclough et al., 2006; Granholm et al., 2006; Temple & Ho, 2005), and two of 
these observed a trend towards significance (Barrowclough et al., 2006; Temple & Ho, 2005). 
One targeted social skills (Granholm et al., 2006), while two focused on reducing persistent 
positive symptoms. One hypothesis about the lack of significant improvements in negative 
symptoms in Barrowclough and colleagues’(2006) and Temple and Ho’s (2005) studies may 
be that selecting participants with severe positive symptoms led to a tendency to concentrate 
on these symptoms, thus neglecting negative symptoms. Another possibility may be that the 
improvements in negative symptoms may have occurred secondary to improvements in 
positive symptoms, and thus represent changes in secondary negative symptoms (King, 1998). 
In support of this hypothesis, Sensky and colleagues (2000) and Tarrier and colleagues (2001) 
found significant reductions in positive and negative symptoms.  Barrowclough and 
colleagues found neither improvement in positive or negative symptoms, and Temple and Ho 
found improvements in only some positive symptoms and no negative symptoms. These 
findings would be in line with the theory that negative symptoms may be a consequence of 
perceived stigma relating to positive symptoms (e.g. Strauss et al., 1989), and therefore as 
26 
 
THERAPIES AND NEGATIVE SYMPTOMS     
positive symptoms reduce, perceived stigma reduces, and negative symptoms improve. 
However in contrast to this, Turkington and colleagues (2008) and Turkington and colleagues 
(2006) found that negative symptoms reduced following CBT, whilst positive symptoms did 
not. These findings are more in line with theories suggesting negative symptoms are caused 
independently of positive symptoms. Perhaps like Meehl (1962) suggested, they are due to an 
inability to relate to others, and through interactions in therapy, these symptoms have 
improved.   
Improvements to specific negative symptoms were documented in five studies. These 
were avolition and apathy (Serruya & Grant, 2009; Johns et al, 2002; Turkington et al., 2006), 
emotional withdrawal, social withdrawal, and lack of spontaneity (Amell & Llandrich, 2008), 
and alogia, anhedonia, and asociality (Tarrier et al., 2001). Emotional withdrawal and social 
withdrawal improvements were not maintained at a six-month follow-up (Amell & Llandrich, 
2008). Improvements in avolition and apathy however were maintained at six-month follow-
up (Serruya & Grant, 2008) and 12-month follow-up (Turkington et al., 2006). Serruya and 
Grant (2008) found that although alogia, anhedonia and asociality did not improve immediate 
after CBT, they could improve six months after therapy. Tarrier and colleagues (2001) found 
a trend towards a significant improvement in alogia, compared to supportive counselling, 
although the absence of within group analysis causes difficulty in comparing these results to 
other studies. Therefore, it seems that CBT can reduce emotional and social withdrawal in the 
short term, and can improve motivation, engagement and pleasure and interest in activities 
and relationships. Further research identifying changes in specific symptoms is required.  
The majority of the effective studies evaluated individual CBT that was either 
formulation-based, or manualised. Out of the three ineffective studies, two assessed group 
interventions (Barrowclough et al., 2006; Granholm et al., 2005), suggesting that individual 
27 
 
THERAPIES AND NEGATIVE SYMPTOMS     
CBT is more effective than group CBT. This concurs with Granholm and colleagues’ (2006) 
observation that greater participation significantly correlated with negative and positive 
symptom improvements. If participation is key to improvements, this may also partially 
explain the effectiveness of individual significant improvements in negative symptoms 
following individual befriending (Sensky et al, 2000) and supportive counselling (Tarrier et 
al., 2001). However, it is questionable whether participation in sessions would cause 
improvements in symptoms to be maintained five years later (Turkington et al., 2008). 
Perhaps a consequence of participation is learning techniques, activating the prefrontal cortex 
and reducing stigma, as suggested by Turkington and colleagues (2008). The only successful 
group interventions (Amell & Llandrich et al., 2008; Knight et al., 2006) focused on 
difficulties that could be considered to be more dependent on social interactions, namely 
social skills and self-esteem.  
Ten studies documented follow-up data, ranging from 18 weeks to five years. 
Barrowclough and colleagues (2006) did not find a significant reduction in negative 
symptoms post intervention or six months later. Three studies showed reductions in negative 
symptoms immediately after CBT but elevations during their follow-up period of 
approximately six months (Amell & Llandrich, 2008), eleven months (Warman et al., 2005), 
and twelve months (Tarrier et al., 1999). Therefore, group CBT (Amell & Llandrich, 2008); 
combined individual and group CBT (Warman et al., 2005); and individual CBT (Tarrier et 
al., 1999) failed to show durable effects in relation to negative symptoms. A shorter follow-up 
period showed improvements in negative symptoms had been maintained for six weeks 
(Knight et al, 2006). Three RCT studies remarkably found even further improvements in 
negative symptoms following individual CBT sessions at 9 months (Sensky et al., 2000), 12 
months (Rector et al., 2003) and 24 months (Startup et al., 2003). Impressively, improvements 
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were still found five years after baseline in Sensky and colleague’s study (Turkington et al., 
2008). Although Turkington and colleagues (2006) did not report within subject changes, 
their follow-up assessment showed that the CBT condition still had significantly less negative 
symptoms than the control condition approximately 10 months after CBT. This suggests that 
individual CBT can produce durable reductions in negative symptoms, for up to five years.  
Only one study (Serruya & Grant, 2009) investigated CBT with an individual who had 
had symptoms for only one year. Other studies of CBT interventions for first-episode 
psychosis were excluded due to including individuals with mood disorders (Jackson et al., 
2008; Lecomte et al., 2008). Therefore further research into the effectiveness of CBT with 
individuals with recent-onset psychoses is advised. Granholm and colleagues (2005) 
documented the oldest mean age of 54.2 years, and this study did not show significant 
changes in negative symptoms after CBT. Whilst, age has been found not to be associated 
with the level of negative symptoms (Schultz et al., 1997), if we consider Strauss and 
colleagues (1974; 1989) theory that negative symptoms may result from social stigmatisation, 
it may be that older individuals have experienced stigma for longer, and thus have had 
negative symptoms for longer, which then may be harder to alleviate.  
It seems unlikely that gender differences can account for all variance in results. Whilst 
males have been found to have a poorer outcome compared to females (Leung & Chue, 2000), 
men participated in all CBT studies, including all of the effective studies. Two studies whose 
entire samples were male also found CBT to be effective at reducing negative symptoms 
(Johns et al., 2002; Warman et al., 2005).  
 
Methodological differences between studies may also account for some variation in 
results. Four studies (Johns et al, 2008; Knight et al., 2006; Warman et al., 2005; Temple & 
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Ho, 2005) did not mention any form of treatment adherence measures, which make it difficult 
to conclude that individuals received the interventions described in the articles. Blinding at 
assessment was not possible in three studies, due to being a case study (Serruya & Grant, 
2009), a waiting list control (Knight et al, 2006), and one experimental group only (Johns et 
al, 2008). One consistent procedure within the methodology was that all individuals were 
randomly assigned to CBT or control conditions, where control groups were included, thus 
eliminating prejudiced selection for specific treatment conditions.  
 
In sum, CBT has been effective at reducing negative symptoms in outpatients, 
inpatients, and acutely unwell inpatients, and in participants with elevated positive symptoms, 
no positive symptoms, or elevated negative symptoms thus far. CBT has also been found to 
be effective for schizophrenia and schizoaffective disorder; with males and females; and with 
adults aged 25 (Serruya & Grant, 2009) and 48.83 years (Warman et al., 2005). Whilst group 
CBT has been successful at reducing negative symptoms (Amell & Llandrich, 2008; Knight et 
al., 2006), it has also been unsuccessful (Barrowclough et al., 2006; Temple & Ho, 2005). 
Negative symptom improvements have been more consistently evidenced following 
individual CBT, which has been formulation based (e.g. Startup et al., 2005) or manualised 
(e.g. Rector et al., 2003). The majority of studies excluded individuals with brain injuries, or 
who misused substances.  This may have been an attempt to eliminate some complexities, 
especially as associations between substance use and psychosis symptoms remain 
inconclusive (Dixon, Haas, Weiden, Sweeney, & Frances, 1990; 1991; Salyers & Mueser, 
2001). However, as lifetime prevalence rates for substance abuse in schizophrenia have been 
found to be as high as 47% to 59.8% (Fowler, Carr, Carter, & Lewin, 1998; Regier et al., 
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1990) it seems important to include individuals who misuse substances in future research, in 
order to test the effectiveness of CBT in a ‘representative’ clinical sample.  
 
Family Interventions 
The NICE guidelines for schizophrenia (NICE, 2009) recommend that family 
interventions should be provided for people with schizophrenia if they are in close contact 
with their families. There is no specific mention of negative symptoms being the target of 
such family interventions.  
Certain aetiology theories of negative symptoms in psychosis fit with the involvement 
of families in treatment. If Strauss and colleagues’ (1974; 1989) theory that negative 
symptoms are seen as a consequence of social stigma is accurate, then perhaps increasing 
other people’s empathy, understanding and involvement may reduce some perceived stigma, 
and accordingly to the theory, this may reduce negative symptoms.  
Two studies evaluated multi-family group-based interventions that facilitated 
problem-solving in families (Bradley et al., 2006; Dyck et al., 2000). All participants were 
non-acute outpatients with schizophrenia or schizoaffective disorder. Both interventions had 
lasted 12 months when published. Bradley and colleagues’ (2006) intervention had 
concluded, whilst Dyck and colleagues (2000) were half way through a two-year intervention. 
Participants were similar ages across the studies (33.6 years and 33 years respectively). 
However, the research is not comparable. Bradley and colleagues engaged individuals with 
schizophrenia and a relative in three sessions, before joining other families in two 
psychoeducation sessions about difficulties. Families then attended bi-weekly, multi-family, 
problem-solving meetings for twelve months. There was no significant change to negative 
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symptoms at the end of the 12 months, or at an 18-month follow-up.  Similarly, Dyck and 
colleagues’ family members attended group psychoeducation sessions, but these occurred 
without the patient. Again, families and patients then attended bi-weekly, multi-family, 
problem solving sessions. Dyck and colleagues’ intervention did significantly reduce negative 
symptoms, specifically avolition and asociality, compared to those receiving standard care. It 
was the negative symptoms involving socialisation with others, therefore, that improved. 
Unfortunately Bradley and colleagues did not report any findings for specific negative 
symptoms.  
Seventy two percent of Dyck and colleagues’ (2000) sample were male, whilst only 
28% of Bradley’s sample was male. It is the study with the greater proportion of males, 
therefore, that showed significant improvements in negative symptoms, despite male gender 
being associated with greater negative symptoms and poorer outcome (Leung & Chue, 2000). 
Ninety four percent of Dyck and colleagues’ sample were white. Bradley and colleagues’ 
(2006) sample included 52% who were English speaking, and 48% who were Vietnamese 
speaking. The ethnic composition may account for some difference, but no evidence was 
found detailing the prognoses of American (Dyck et al, 2000), Australian, and Vietnamese 
(Bradley et al., 2006) people with psychosis.  
 
Summary of Family Interventions 
As only two family interventions were identified, limited conclusions can be made 
regarding the impact of family interventions in reducing negative symptoms. With regards to 
methodology, both studies used manualised interventions. However, whilst Dyck and 
colleagues (2000) observed videotapes of sessions to check fidelity, Bradley and colleagues 
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(2006) did not formally assess fidelity. Both studies included individuals who misused 
substances. These individuals were not differentiated in analyses and therefore the influence 
of these substances on therapeutic outcomes was not assessed. The durability of the treatment 
also remains questionable, as no significant reduction in negative symptoms was found after 
18 months (Bradley et al., 2006), and Dyck and colleagues’ participants were still receiving 
their intervention. 
Several studies assessing family interventions were eliminated from this review due to 
including additional individual therapies (e.g. Grawe, Falloon, Widen, & Skogvoll, 2006). 
Further studies were excluded due to not directly measuring negative symptoms (Berglund, 
Vahlne, & Edman, 2003; Leff, Sharply, Chisholm, Bell, & Gamble, 2001). 
Dyck and colleagues (2000) and Bradley and colleagues (2006) in their studies 
covered an adult population age range from 18 years to 55 years. Hence it remains unclear 
whether similar findings would be made with an older population. Family interventions with 
individuals who are acutely unwell and who are not receiving any other therapeutic 
intervention also need to be studied.  
 
Cognitive Remediation Therapy 
It has been suggested that cognitive deficits found in psychosis increase with every 
episode of psychosis, and whilst they may convalesce somewhat as other symptoms diminish, 
some impairments remain (e.g. Wykes & Reader, 2005). Cognitive deficits have been 
consistently associated with the presence of negative symptoms (Harvey, Koren, Reichenberg, 
& Bowie, 2006; Heydebrand et al., 2004; Johnson-Selfridge & Zalewski, 2001).  CRT aims to 
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train individuals in cognitive skills, which are said to be impaired, through repetition and skill 
acquisition techniques. Reflection and metacognition aims to adapt the skills to real life 
settings (Wykes & Reeder, 2005). Six studies were identified that described the impact of 
CRT on negative symptoms in psychosis. Five of these produced a favourable outcome and 
one did not.  
With regards to RCTs, Wykes and colleagues (2007) evaluated individual CRT that 
aimed to improve working memory, cognitive flexibility, and planning, for people with 
schizophrenia and social difficulties. Alongside significant improvements in working 
memory, there was a reduction in negative symptoms following CRT, compared to ‘usual 
treatment’. Although statistical analyses for negative symptoms were not present in the 
original paper (Wykes et al., 2007), negative symptoms were analysed in a later publication 
(Wykes et al., 2009), which showed that the ’younger cohort’ of 17 to 39 year olds, showed 
significant improvements in negative symptoms following CRT, but the ‘older cohort’ of 40 
to 62 year olds did not.  
A more recent RCT compared computerised CRT for attention, memory and cognitive 
problems, plus group-based social cognitive skills training, to ‘enriched supportive therapy’ 
for individuals with schizophrenia or schizoaffective disorder (Eack et al., 2009). The 
enriched supportive therapy included individual sessions focusing on illness and stress 
management. CRT significantly reduced negative symptoms, compared to the enriched 
supportive therapy at one year. CRT also improved neurocognitive functioning, anxiety and 
depression. These improvements were maintained after two years. These results suggest that 
components of the ETAU were not as effective at reducing negative symptoms as CRT. 
However, it remains unclear what the ‘active’ component of CRT was. It could be the number 
of sessions of CRT, as it was noted that this was not matched across the two interventions. 
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Alternatively, repetition of tasks in CRT may facilitate skill acquisition, and potentially 
reduce negative symptoms by possibly increasing pleasure or motivation. The CRT in this 
study differed from Wykes and colleagues’ (2007) RCT as it included social cognitive skill 
CRT and memory CRT. Eack and colleagues (2009) also used computer programs to deliver 
CRT. 
Bellucci, Glaberman, and Haslam (2003) similarly assessed computer-assisted CRT 
for outpatients with schizophrenia or schizoaffective disorder. Using the wait-list control 
method, they found that after CRT for attention and memory there were significant 
improvements in negative symptoms, verbal memory, and attention, compared to controls. 
Specifically, anhedonia, affective flattening and attention impairments significantly reduced.  
The CRT appeared to be similar to Eack and colleagues’ (2009) but without the social 
cognitive skills sessions, and yet it still showed improvements in negative symptoms. Perhaps 
this suggests the memory CRT was, at least in part, responsible for these improvements in 
both studies.  
 Bark and colleagues (2003) assessed CRT with inpatients with schizophrenia or 
schizoaffective disorder, and who had problem solving and memory difficulties. Overall, the 
CRT conditions showed significant reductions in negative and positive symptoms compared 
to the control group, and improvements were maintained four weeks after therapy. When CRT 
was divided into problem-solving or memory CRT, the problem-solving CRT group 
demonstrated significant improvements in negative symptoms and the memory CRT group 
did not.  This result seems contradictory to the significant improvements found in Eack and 
colleagues’ (2009) and Bellucci and colleagues’ (2003) studies following CRT for memory 
and attention. Bark and colleagues’ CRT was 10 sessions long, and was for inpatients, whilst 
Bellucci and colleagues, and Eack and colleagues worked with outpatients for 16 and an 
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extensive 60 sessions of CRT for memory respectively, which may have contributed to their 
effectiveness at reducing negative symptoms.  
Penadés and colleagues (2002) conducted CRT for social perception, attention and 
conceptual skills, with a small sample of outpatients with schizophrenia characterised by 
negative symptoms and cognitive deficits. Again, this CRT intervention significantly 
improved negative symptoms, and verbal memory, as well as associative learning, abstraction 
and executive functions. Unfortunately the study did not include a control group, thus making 
validation of CRT effectiveness difficult.   
The one study that did not show a significant decrease in negative symptoms 
following CRT was an RCT with inpatients who had schizophrenia by Vauth and colleagues 
(2005). Three interventions were compared, namely group-based computer-assisted CRT for 
verbal memory and planning; a group-based intervention focusing on skills to manage 
negative symptoms, and controls receiving no group intervention. Negative symptoms 
reduced slightly, but not significantly within or between the three groups. These participants 
had milder negative symptoms at baseline than other studies, with means across the three 
groups ranging from 8.7 to 10.4 on the Positive and Negative Syndrome Scale (PANSS; Kay, 
Fiszbein, & Opler, 1987). Other, effective, CRT studies presented mean total negative 
symptoms at baseline as 18.6 (Wykes et al., 2007), 19.9 (Bark et al., 2003), and 23.25 
(Penadés et al., 2002) using the PANSS. Perhaps CRT is more effective at improving severe 
negative symptoms. Drop-out rates within Vauth and colleagues’ study were high, and the 
authors did not report whether negative symptoms differed between those who dropped out 
and those who remained in the study. Whilst the majority of research was conducted with 
outpatients, Vauth and colleagues’ study was conducted with inpatients. However, Bark and 
colleagues’ (2003) smaller study was also conducted with inpatients, and produced favourable 
36 
 
THERAPIES AND NEGATIVE SYMPTOMS     
results. This tentatively contraindicates setting as accounting for the different outcome in 
Vauth and colleagues’ study. 
  
 Summary of CRT 
 A tentative deduction from the studies reviewed is that CRT may be effective at 
reducing negative symptoms in people with schizophrenia and schizoaffective disorder who 
have severe negative symptoms before therapy. Mental healthcare setting, gender, or 
diagnosis, may not affect the impact of the therapy. Wykes and colleagues (2009) found that 
the older cohort in their sample did not show significant improvements in negative symptoms 
following CRT, but the younger cohort did. However Vauth and colleagues (2005) study had 
the second lowest mean age and found no significant benefit of CRT for negative symptoms. 
Therefore the relationship between age and the effectiveness of CRT remains unclear, and 
requires further research. Improvements to specific negative symptoms were only mentioned 
in one study (Bellucci et al., 2003), where anhedonia and flattened affect significantly 
improved following CRT. The durability of CRT interventions to reduce negative symptoms 
was only assessed by Bark and colleagues (2003), who found improvements in total negative 
symptoms were maintained four weeks after intervention. 
 The three most recent studies were RCTs, whilst the earlier three took place in clinical 
settings. All studies randomly allocated participants to groups, with the exception of Penadés 
and colleagues (2002) who only had a CRT group. Vauth and colleagues (2005) stratified 
their participants by typical or atypical antipsychotic medication regimes, and three studies 
found no difference in medication between their CRT participants and control participants. 
Eack and colleagues (2009) did not mention medication and, therefore, it cannot be ruled out 
37 
 
THERAPIES AND NEGATIVE SYMPTOMS     
that different medications did not affect symptoms across conditions. This was also the only 
study where assessors were not blind to treatment, and therefore this may have biased their 
results. Noticeably, the assessors in Penadés and colleagues’ study also knew that all 
participants received CRT. Treatment fidelity was checked within Wykes and colleagues 
study through observations and participants’ paper exercises. No other papers discussed 
fidelity checks, although Eack and colleagues documented that clinical supervision occurred. 
Three interventions were wholly, or partly, computer-based CRT, and therefore the variability 
of therapy was limited by the flexibility of the software (Bark et al., 2003; Bellucci et al., 
2002; Vauth et al., 2005).  
 Some studies were omitted from the review due to a lack of negative symptom 
measurements, or analysis of said measurements (e.g. Blairy et al., 2008; Kurtz, Seltzer, 
Fujimoto, Shagan, & Wexler, 2009). Therefore, whilst there is a vast amount of research 
regarding the effectiveness of CRT on cognitive abilities (e.g. Kurtz, Seltzer, Shagan, Thime, 
& Wexler, 2007; van der Gaag, Kern, van den Bosch, & Liberman, 2002) the effect of CRT 
on negative symptoms is in its infancy. 
 The reviewed research included individuals who had had a diagnosis of psychosis for 
six months (Bellucci et al., 2003) or longer. Research into the effectiveness of CRT with 
people at different stages of psychosis, such as close to onset, should be pursued. 
 
Body-Oriented Psychological Therapy 
Body-oriented psychological therapy (BPT), or ‘body psychotherapy’, has origins in 
psychoanalytic psychotherapy (Staunton, 2002). The premise is that it goes beyond the 
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language barriers often found in individuals with mental health difficulties. Individuals use 
movement to become refocused on their bodies, and to be informed of reality from this 
connection. The supposition to this theory is that by reconnecting with the realities of their 
bodies, individuals will also reconnect with their emotions (Röhricht & Priebe, 2006). 
Two papers were found detailing the same pilot RCT of group-based manualised BPT 
with individuals with schizophrenia and severe negative symptoms (Röhricht, Papadopoulos, 
Suzuki, & Priebe, 2009; Röhricht & Priebe, 2006). The BPT group showed significantly 
lower negative symptoms post therapy compared to 21 people who received supportive 
counselling. Specifically, blunted affect and motor retardation were found to have reduced 
significantly following BPT. These improvements remained four months later. In further 
analysis, increased body demarcation predicted decreases in negative symptoms, whilst 
egopathology and body orientation were not predictive of change (Röhricht et al., 2009). 
There were no significant differences in demographic variables or antipsychotic medications 
between conditions, and therefore differences between results were likely to be due to the 
intervention. BPT was manualised, which can help to minimise differences between the 
treatments received. The supportive counselling, however, was not reported to be manualised, 
and neither treatment was documented to be evaluated for treatment fidelity. 
In sum, all that can be concluded currently is that BPT is more effective than 
supportive counselling at reducing blunted affect and motor retardation in a small group of 
male and female outpatients with schizophrenia and severe negative symptoms at baseline. 
Inpatients, those with less negative symptoms, people in early stages of psychosis, those with 
other types of psychosis, and individuals older than 55 years are currently unstudied. The 
results from this RCT suggest that improvements to negative symptoms stayed until at least 
four months after BPT was complete. However, if this intervention is to be compared to CBT, 
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where total negative symptoms have been improved for up to nearly five years, further 
follow-up assessments of BPT is required.  
 
Discussion 
Clinical Implications 
The research reviewed suggests that there are psychological therapies that can improve 
negative symptoms in psychosis. Only four out of 26 studies failed to find a significant 
reduction in negative symptoms following a psychological intervention, and two of these 
found trends towards significance (i.e. Barrowclough et al., 2006; Temple & Ho, 2005). 
Whilst there is a publication bias against studies that do not find significant results, especially 
if these include small samples (Geddes, Freemantle, Harrison, & Bebbington, 2000) the 
proportion of effective studies compared to ineffective studies are encouraging.  All but one 
RCT (Barrowclough et al., 2006) found negative symptoms diminished following 
psychological interventions. There is a need for a family intervention RCT to clarify the 
findings of the two clinical studies (Bradley et al., 2006; Dyck et al., 2000).  
CBT has the most evidence for reducing negative symptoms. CBT also improved the 
broadest range of negative symptoms, including alogia, anhedonia and asociality (Tarrier et 
al., 2001), social and emotional withdrawal (Amell & Llandrich, 2008) and avolition (Serruya 
& Grant, 2002; Johns et al., 2002). BPT led to improvements in flattened affect and motor 
retardation. Improvements in anhedonia, inattention and flattened affect were found following 
CRT, and family interventions produced decreases in avolition and asociality. CBT reduced 
avolition in some studies. BPT and CRT reduced negative symptoms when baseline negative 
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symptoms were severe, while CBT and family interventions proved to reduce negative 
symptoms irrespective of severity before therapy. These observations suggest that a variety of 
therapies, or techniques from these therapies, may be required to produce improvements in all 
negative symptoms. It also suggests different therapies may be more suitable for individuals 
with different symptoms. The evidence emphasises the importance of experienced clinicians 
who are able to correctly identify specific symptoms, and should direct professionals towards 
either individualised formulation-driven care (e.g. Startup et al., 2005) and/or manualised-
based intervention with proven effectiveness (e.g. Dyck et al., 2000; Rector et al., 2003; 
Röhricht & Priebe, 2006).  
The effectiveness of group-based interventions appears more variable than individual 
therapy. Two out of five CBT group interventions (Barrowclough et al., 2006; Granholm et 
al., 2006), and one out of two multi-family interventions (Bradley et al., 2006) failed to show 
improvements in negative symptoms. However, group therapy proved successful when 
deficits reflected social difficulties, such as problems with social skills (Amell & Llanrich, 
2008) and low self-esteem (Knight et al., 2006). No group intervention was found to be 
superior in reducing negative symptoms than individual therapy, although some therapies, 
such as BPT and CBT for self-esteem, only occurred in group format. 
The durability of family interventions was only assessed in one study, where no 
improvements in negative symptoms were found post therapy or six months later (Bradley et 
al., 2006). All other interventions found improvements could be maintained for different 
periods. CRT and BPT showed their improvements to be maintained four weeks after 
intervention (Bark et al., 2003; Röhricht & Priebe, 2006). The durability of CBT ranged from 
six weeks (Knight et al., 2006) to five years (Turkington et al., 2008). Conversely, some CBT 
studies found that improvements were lost between six (Amell & Llandrich, 2008) and 12 
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months (Tarrier et al., 1999) after intervention. This suggests CBT would be a superior 
therapy for the long-term treatment of negative symptoms, but also highlights some need for 
follow-up observation or ‘booster’ intervention sessions during the 6-12 month period post-
intervention.  The quantity of positive findings regarding CBT for negative symptoms may 
also reflect the advanced nature of the CBT research compared to the other, less studied 
interventions.  
Whilst the research reviewed suggest psychological therapies can reduce negative 
symptoms, Birchwood and Trower (2006) raised the point, with reference to CBT for 
psychosis, that perhaps the role of psychological therapies should be to reduce distress. They 
argue that if neuroleptic medication is used to reduce symptoms, psychological therapies 
should concentrate on treating the person’s emotional responses, which in principle would 
mean more holistic improvements could occur, rather than both medication and psychological 
therapies only targeting symptoms. 
 
Research Implications 
All of the research used different interventions and different methods to assess them. 
The therapists professions, experience, and training differed, as did the mental health settings. 
A variety of assessment tools were used to assess negative symptoms, although the common 
utilisation of the PANSS did allow some comparison of results. Antipsychotic medication 
may also have confounded some results.   
The most consistent factor across the studies appeared to be the exclusion criteria. 
Almost all CBT studies excluded individuals with organic brain injuries or substance misuse. 
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Similarly, CRT studies tended to neglect individuals with IQs below 80 or substance misuse. 
Therefore, the impact of psychological therapies in reducing negative symptoms for these 
individuals is yet to be determined. This is particularly alarming with regards to substance 
abuse, due to high proportions of individuals with psychosis who misuse substances (Regier 
et al., 1990; Fowler et al., 1998). Family intervention studies included individuals who 
misused substances, but did not differentiate results for misusers and non-misusers (Bradley 
et al., 2006; Dyck et al., 2000). These studies showed inconsistent findings, and perhaps the 
effects of substance misuse confounded the results.  
Many papers are starting to emerge that focus on integrative therapies, such as social 
skills groups for individuals whose families also attended psychoeducation (Valencia, Rascon, 
Juarez, & Murow, 2007), or individual and group CBT for patients and psychoeducation for 
families (Drury, Birchwood, & Cochrane, 2000). If it is accurate that different therapies 
alleviate different negative symptoms, a combination of psychological interventions may 
produce a broad range of improvements. However, therapeutic components of interventions 
have not been identified at present. Perhaps repetitions of some studies, with methodical 
changes to interventions need to be explored in order to comprehensively ascertain any 
therapeutic components that may produce positive outcomes.  
The literature to date provides strong evidence that four different psychological 
therapies can improve negative symptoms in psychosis, and these improvements can be 
greater than those seen when such interventions are not included in people’s mental health 
care. 
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Abstract 
Background: Cannabis use has consistently been found to increase the risk of relapse, and 
decrease treatment compliance in people with schizophrenia. However, the effect of cannabis 
on positive and negative symptoms remains unclear, and is currently unstudied in an 
Assertive Outreach population. 
Method: Thirty nine people with schizophrenia or schizoaffective disorder were recruited 
from four Assertive Outreach Teams. During an individual interview, information regarding 
current mental health, substance misuse, and substance dependence was collected.  
Results: There was no significant difference between the severity of total negative symptoms, 
total positive symptoms, or specific negative symptoms, being experienced by cannabis users 
(n=16) and non-cannabis users (n=20). Surprisingly, a large proportion (65.0%) of the non-
cannabis users used other substances, as did the cannabis users (87.5%). 
Conclusion: The lack of association between cannabis use and negative symptoms differs 
from some research. The role of cannabis in symptoms being experienced by an Assertive 
Outreach population remains unclear due to three factors. The sample may have been too 
small to detect any differences. The history, particular the onset, of cannabis and other 
substance use may affect current symptoms. The third factor is that both groups were poly-
substance users, which may impact on symptom presentation.   
 
Keywords: Schizophrenia, schizoaffective disorder, negative symptoms, cannabis, substance 
use. 
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Introduction 
Alcohol and drug use are widely recognised as problematic in those with mental health 
difficulties. The National Institute of Mental Health (NIMH) Epidemiologic Catchment Area 
study in the USA found that 47% of participants with schizophrenia or schizophreniform 
disorder also met the criteria for alcohol or substance abuse-dependence within their lifetime 
(Regier et al., 1990). Indeed, people with schizophrenia or schizophreniform disorder were 
4.6 times more likely to have a substance misuse disorder compared to the general population. 
Similar lifetime prevalence (48.3%) has been reported in Sweden (Cantor-Graae, Norström, & 
McNeil, 2001) and Australia (59.8%) (Fowler, Carr, Carter, & Lewin, 1998). A more recent 
NIMH study reported 60% of their USA sample with schizophrenia used substances at the 
time of the trial, and 37% demonstrated a substance abuse disorder (Swartz et al., 2006). In 
the UK, 36.3% of an inner city community mental health sample of people with severe mental 
illness were found to have experienced problems relating to their substance use in the 
previous 12 months (Menezes et al., 1996). In Birmingham, UK, 24% of people diagnosed 
with a severe mental health problem experienced problematic substance use in the previous 
year. The majority had a diagnosis of schizophrenia, schizotypal or delusional disorders; and 
were male (Graham et al., 2001). In that study Assertive Outreach Teams (AOTs) had a 
significantly greater amount of individuals with a substance impairment/dependency on their 
caseload than substance misuse, primary care, and continuing care services. That is, 26 to 
45% of all of the AOTs’ caseloads. Younger age, lower levels of education and being male 
have been found to be associated with greater substance misuse in schizophrenia (Dixon, 
1999; Salyers & Mueser, 2001). Alcohol dependence in schizophrenia has been associated 
with younger age, male gender, and use of other substances (Drake, Osher, & Wallach, 1989).  
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Effects of Substance Use on Psychosis 
The impact of substances on psychosis symptoms remains unclear, due to varying 
research findings. For example, an early review of the literature indicated that the majority of 
studies found exacerbated psychotic symptoms in substance misusers with schizophrenia 
(Dixon, Haas, Weiden, Sweeney, & Frances, 1990). However, they also found that whilst 
opiates increased negative symptoms, amphetamines and benzodiazepines lowered them. 
Others have found lower levels of negative symptoms in substance misusers compared to 
non-users (Dixon, Haas, Weiden, Sweeney, & Frances, 1991; Salyers & Mueser, 2001). One 
study suggested that greater symptom severity increased people’s motivation to use 
substances (Spencer, Castle, & Michie, 2002).  
Substance misuse in psychosis has been associated with greater rates of 
rehospitalisation (Dixon et al., 1990; Drake et al., 1989; Gupta, Hendricks, Kenkel, Bhatia, & 
Haffke, 1996; Swofford, Kasckow, Scheller-Gilkey, & Inderbitzen, 1996), poorer quality of 
life (Addington & Addington, 1997), poorer interpersonal relationships (Salyers & Mueser, 
2001), higher rates of suicide attempts (Gut-Fayand et al., 2001) and poorer medication 
compliance (Dixon, 1999; Drake et al., 1989; Owens, Fischer, Booth, & Cuffel, 1996). 
Substance use plus medication noncompliance has been associated with even greater 
symptoms (Owens et al., 1996), greater numbers of serious violent acts (Swartz et al., 1998), 
and faster readmission rates (Hunt, Bergen, & Bashir, 2002). In sum, it appears that substance 
misuse among those with psychosis may exacerbate some symptoms of psychosis, ameliorate 
others, and have a negative impact on the course and treatment of psychosis. 
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Cannabis Use Prevalence in Psychosis 
In several countries, cannabis has been found to be the second most commonly used 
and misused substance by people with severe mental health problems, after alcohol (Cantor-
Graae et al., 2001; Graham & Maslin, 2002; Fowler et al., 1998; Mueser et al., 2000). In the 
UK and USA the third most commonly used substance by those with psychosis is cocaine 
(Graham & Maslin, 2002; Mueser et al., 2000). In Australia, however, it was reported that 
alcohol, cannabis, and amphetamines were the most commonly used substances (Fowler et al., 
1996). In a sample of first-episode psychosis, cannabis was found to be the most misused 
substance, more so than alcohol (Cantwell et al., 1999). 
A recent review of cannabis use in psychosis calculated mean prevalence rates for 
current use, use in the previous twelve months, and lifetime use to be 23%, 29.2% and 42.1% 
accordingly. With regards to misuse, they reported 11.3% had misused in the last month, 
18.8% in the last 12 months, and 42.1% in their lifetime (Green, Young, & Kavannagh, 
2005). Within an urban area in the UK, 43% of people with a severe mental illness in 
Assertive Outreach settings were found to be misusing cannabis currently (Graham & Maslin, 
2002). Of those with cannabis impairment-dependence, 81% had a diagnosis of 
schizophrenia, schizotypal or delusional disorder. Lifetime prevalence rates of cannabis use in 
first-episode psychosis were 60% in a Canadian sample (Archie et al., 2007) and 80.3% in a 
UK sample (Barnett et al., 2007). These studies indicate that a considerable number of 
individuals with psychosis use cannabis. It is, therefore, of clinical importance that the effects 
of cannabis on psychosis are explored, in order to improve the effectiveness and delivery of 
interventions addressing substance misuse, symptoms, and functioning in psychosis. 
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Effects of Cannabis in Psychosis 
Cannabis use and relapses/rehospitalisations  
Two studies have found that cannabis misuse during or preceding first hospitalisation 
is correlated with more, and earlier relapses, when compared to non-misusers (Caspari, 1999; 
Linszen, Dingemans, & Lenior, 1994). The quantity of cannabis use seems pertinent, as heavy 
use was indicative of more relapses (Linszen et al., 1994). A study of an early-onset sample 
concluded that cannabis use at first admission and 12 months later predicted greater relapses, 
treatment noncompliance, and increased stress (Martinez-Arevalo, Calcedo-Ordoñez, & Varo-
Prieto, 1994). More recent first-episode psychosis studies similarly found that cannabis use 
reduced medication compliance (Coldham, Addington, & Addington, 2002) increased the 
number of relapses (Pencer, Addington, & Addington, 2005), and that psychotic relapses can 
then predict a return to cannabis use (Hides, Dawe, Kavanagh, & Young, 2006). 
 
 Cannabis and Positive Symptoms of Psychosis 
‘Psychosis’ is often used to describe a group of psychotic disorders (DSM-IV-TR; 
American Psychiatric Association, 2000) including schizophrenia, schizoaffective disorder, 
delusional disorder, and specific psychotic disorders. It has been theorised that symptoms of 
schizophrenia may occur in two distinct clusters, namely positive symptoms and negative 
symptoms (e.g. Crow, 1980; Lewine, Fogg, & Meltzer, 1983). ‘Positive symptoms’ refers to 
symptoms that are additional to experiences in the general population, such as delusions, 
thought disorder, and hallucinations. ‘Negative symptoms’ tends to describe a loss of emotion 
or behaviour (e.g. Birchwood, Hallett, & Preston, 1989), such as blunted affect, decreased 
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motivation (avolition), reduced pleasure (anhedonia), or poverty of speech (alogia).  
Some studies have found no significant correlation between positive symptoms of 
psychosis and cannabis misuse (e.g. Compton, Furman, & Kaslow, 2004; Dubertret, Bidard, 
Adès, & Gorwood, 2006). However, studies of early-onset psychosis have reported elevated 
positive symptoms in cannabis users (e.g. Addington & Addington, 2007; Grech, Van Os, 
Jones, Lewis, & Murray, 2005). Also, Caspari (1999) found that young individuals who 
misused cannabis prior to their first hospitalisation had significantly greater ‘thought 
disturbance’ and hostility than non-misusers two and five years following admission. Bersani, 
Orlandi, Kotzalidis, and Pancheri (2002), however, found in their sample of older males 
(mean age: 32.13 years) who had had psychosis for a mean duration of 10.31 years, that 
cannabis users experienced less thought disorder than nonusers. Interestingly, they also found 
that individuals whose schizophrenia preceded their cannabis use had significantly greater 
positive symptoms than those whose cannabis use preceded schizophrenia.  
 
 Cannabis and Negative Symptoms of Psychosis  
Similar to positive symptoms, the profile of negative symptoms in individuals who use 
or misuse cannabis is not consistent across studies. Some studies found no significant 
difference between the negative symptoms experienced by cannabis users and non-users 
(Boydell et al., 2007; Grech et al., 2005) or misusers and non-misusers (Addington & 
Addington, 2007; Kovasnay et al., 1997) in individuals with first-episode psychosis.  In 
contrast, Compton and colleagues (2004) found that their first-episode psychosis participants 
who were dependent on cannabis experienced significantly fewer negative symptoms than the 
non-dependent participants. Peralta and Cuesta (1992) found no significant difference in total 
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positive or negative symptoms between cannabis misusers and non-misusers in people under 
the age of 35 years with schizophrenia. However, they did find significantly less alogia in 
cannabis misusers than non-misusers. Two studies of “chronic” inpatients, who had had 
psychosis for an average of 9.61 years or more, found significantly fewer negative symptoms 
in cannabis users and misusers (Bersani et al., 2002; Dubertret et al., 2006), specifically 
avolition and apathy (Dubertret et al., 2006) and also affective flattening, alogia, anhedonia-
asociality, and attention (Bersani et al., 2002). When other substance misuse was taken into 
account, Bersani and colleagues (2002) found that whilst polysubstance misusers experienced 
significantly less negative symptoms than the cannabis users, the cannabis users did not show 
less negative symptoms than the nonusers. In contrast to this, Dubertret and colleagues (2006) 
still found less avolition-apathy in the ‘pure’ cannabis misusing group compared to the non-
misusing group. Batki, Leontieva, Dimmock, and Ploutz-Snyder (2008) discovered that 
negative symptoms in their outpatient sample were negatively correlated to frequency of 
cannabis use by people who had schizophrenia or schizoaffective disorder and alcohol 
dependence. They pinpointed less ‘blunted affect’, ‘difficulty in abstract thinking’ and ‘lack 
of spontaneity and flow in conversation’ on the Positive and Negative Syndrome Scale 
(PANSS; Kay, Fiszbein, & Opler, 1987) was associated with more days of cannabis use. They 
also found that when positive symptoms were greater than negative symptoms, this was 
associated with more days of cannabis use. 
From the literature it seems that cannabis use has been associated with greater and 
more rapid relapse, and less compliance with treatment. Findings are fairly mixed with 
regards to positive symptoms, as some cannabis users have been found to experience greater 
positive symptoms, others have experienced less, and some have shown similar levels as non-
misusers. In first-episode psychosis samples, no association between negative symptom 
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severity and cannabis use has been found. However, in samples not specifically in their first 
episode, fewer negative symptoms have been found in those using or misusing cannabis. It 
has been suggested that the chronology of schizophrenia and cannabis use may affect any 
interactions between negative symptoms and cannabis (e.g. Bersani et al., 2002). 
 
The Impact of Negative Symptoms in Psychosis 
Research suggesting that negative symptoms are associated with the course and 
prognosis of psychosis is reviewed below. In fact, it has been discovered that the greater the 
severity of negative symptoms, the longer the duration of psychosis (Breier, Schreiber, Dyer, 
& Picker, 1991). It is important to note, however, that no causal links have been established, 
and therefore it may be that negative symptoms affect prognosis and functioning, or those 
difficulties in functioning cause further negative symptoms.  
 
 Negative Symptoms and Depression 
Depressive symptoms have been found to be greater in those with schizophrenia than 
in the general population (e.g. Zisook et al., 1999). In addition, those who use or misuse 
cannabis have been found to have even greater depression in schizophrenia (Cuffel & Chase, 
1994; Scheller-Gilkey, Thomas, Woolwine, & Miller, 2002). Depression is likely, therefore, 
to be experienced alongside the symptoms of psychosis. Depression, especially ‘postpsychotic 
depression’, and negative symptoms may be confounded (Sommers, 1985). The majority of 
research has concluded that depression and negative symptoms are not correlated (e.g. 
Herbener & Harrow, 2001; Lysaker, Bell, Bioty, & Zito, 1995; Zisook et al., 1999). 
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Birchwood, Iqbal, Chadwick, and Trower (2000) found that depression that occurred within 
the psychotic stage of psychosis would decrease as psychosis remitted, but depression that 
occurred in the post psychotic phase of psychosis was not associated with positive or negative 
symptoms. Some researchers, however, have found that some depressive symptoms are 
positively correlated with negative symptoms, namely anhedonia/asociality and 
avolition/apathy (Sax et al., 1996). Kulhara and colleagues (1989) found that total depressive 
symptoms, lack of energy, and slowness correlated with negative symptoms whilst 
confirming other depressive symptoms such as somatic concern, anxiety, guilt, tension, and 
depressive affect, did not. It is essential that depressive and negative symptoms are 
differentiated as they require different treatments. For example, tricyclic antidepressant 
medication has been found to reduce depression in psychosis when used with neuroleptic 
medication, but they do not have any significant effect on reducing negative symptoms 
(Plasky, 1991). Also whilst Cognitive Behavioural Therapy is recommended for the treatment 
of depression (NICE, 2007), it is not specifically recommended for negative symptoms in 
schizophrenia (NICE, 2009). 
  
Negative Symptoms and Functioning 
Severe negative symptoms during psychosis have been associated with lower 
premorbid IQ levels (Brill et al., 2009), severe cognitive deficits (Harvey, Koren, 
Reichenberg, & Bowie, 2006) and a longer lifetime duration of hospitalisation (Pogue-Geile 
& Harrow, 1984). Negative symptoms have also been linked to difficulties with daily 
functioning. Poorer overall functioning at the onset of the illness was associated with greater 
negative symptoms between two and eight years into the course of illness (Siegel et al., 2006). 
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Similarly, when individuals’ functioning was assessed one year prior to initial hospitalisation 
for psychosis, lower premorbid functioning was associated with greater negative symptoms, 
which consequently then predicted poorer postmorbid functioning (Brill et al, 2009; Pogue-
Geile & Harrow, 1984).  
Greater severity of current negative symptoms have been associated with poorer social 
functioning (Bowie, Reichenberg, Patterson, Heaton, & Harvey, 2006; Breier et al., 1991; 
Brill et al., 2009; Hwu, Tan, Chen, & Yeh, 1995; Pogue-Geile & Harrow, 1984); poorer work 
functioning (Breier et al., 1991; Brill et al., 2009; Pogue-Geile & Harrow, 1984); and reduced 
independent functioning (Breier et al., 1991). Bowie and colleagues (2006) found that whilst 
functional capacity was the most predictive factor for functional outcome, elevated negative 
symptoms reduced functional outcome even further. This suggests that whilst individuals’ 
functioning can be affected by their abilities to know how to conduct a task, negative 
symptoms seem to exacerbate difficulties in performing those skills on a day-to-day basis. 
 
Negative Symptoms and Assertive Outreach Teams 
Engagement with mental health services has been proven more difficult for younger 
service-users, males, people from ethnic minorities, people with poorer social functioning, 
and substance users (Kreyenbuhl, Nossel, & Dixon, 2009). Assertive Outreach Teams (AOTs) 
have been established across the UK in order to provide mental health care for individuals 
with psychosis and other mental health difficulties that have disengaged from other services.  
AOT service users in the UK have been shown to have higher levels of substance use 
than people being cared for by Community Mental Health Teams (CMHTs). For example, as 
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described previously, between 26 and 48% of all people being cared for by AOTs were 
dependent on substances (Graham et al., 2001; Commander, Sashidharan, Rana, & Ratnayake, 
2005; Fakhoury et al., 2006; Schneider, Brandon, Woofe, Carpenter, & Paxton, 2006), 
compared to between 3% and 27% of CMHT service users (Carrà & Johnson, 2009; 
Schneider et al., 2006; Weaver et al., 2001). In one AOT sample, 84.8% of the individuals 
who were dependent on substances in the past six months fitted criteria for cannabis-abuse 
(Fakhoury et al., 2006). 
AOT service users have been found to have more severe symptoms of mental illness, 
with 95% of individuals accessing AOTs in North East England being regarded as ‘psychotic’ 
by their care co-ordinators, compared to 31% and 45% in CMHTs (Schneider et al., 2006). 
They also found that almost 83% of individuals in AOTs were admitted to hospital at least 
once in a two-year period compared to 26% and 28% in two CMHTs, suggesting higher 
symptom levels and thus greater relapses. Ten percent of the AOT population demonstrated 
current self neglect, compared to eight percent in one CMHT and 4 percent in another 
(Schneider et al., 2006). In an audit of workload within an AOT, Wharne (2005) consistently 
found twelve problems that people experienced that required additional support from the 
AOT. These were: childhood relationships, substance misuse, financial crises, self harm, 
hospitalisation, difficulties with daily living skills, comorbid diagnoses, social exclusion, 
forensic issues, inactivity, housing issues, and untreated mental health problems. Wharne 
(2005) acknowledged that the majority of these difficulties may result in an escalation of 
symptoms, although no formal assessment of symptoms appeared to be included in the audit.  
In sum, many individuals on AOT caseloads are experiencing problematic life events 
and a number are experiencing negative symptoms which impact on functioning and 
prognosis. Also, the increased use of substances by this group relative to CMHTs, and the 
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high proportion of substance-misusers showing cannabis dependence (Fakhoury et al., 2006) 
indicates that the effects of cannabis require further investigation in samples of AOT service 
users. 
 
Aims of the Current Research  
1) To ascertain whether people with schizophrenia, schizotypal or delusional disorders 
who are under the care of AOTs experience different negative symptoms when they 
are users of cannabis, compared to those who do not use cannabis.  
2) To assess the extent to which depression and negative symptoms co-occur in those 
people who use cannabis and those who do not. 
 
Accordingly the hypotheses were: 
1) That individuals who have schizophrenia, schizotypal or delusional disorders and use 
cannabis would experience less severe negative symptoms than those who do not use 
cannabis. 
2) That any difference between the severity of negative symptoms observed in 
participants who use cannabis compared to those who do not, would remain when 
depression had been controlled. Thus depression would not account for the 
differences.  
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Method 
Design 
A between-subject design was used to investigate any associations between negative 
symptoms, cannabis use and depression.  A natural groups design meant that group 
assignment was ascertained depending on whether participants reported using cannabis or not. 
If participants had used cannabis at least once per week in the past 30 days, as measured by 
Section B of the Maudsley Addiction Profile (Marsden et al., 1998), they were allocated to the 
‘cannabis users’ group, and if they had not used cannabis in the last 30 days, they were 
assigned to the ‘non-cannabis users’ group.  
 
Participants 
Participants were recruited from four out of eight AOTs within a large NHS Trust in 
Birmingham. Two teams were based within the inner city area, where high prevalence rates of 
substance misuse have been recorded in the past (Carrà & Johnson, 2009; Graham & Maslin, 
2002). These two AOTs also covered geographical areas that had greater proportions of 
income, employment, education, and health deprivation compared to outer city areas in 2001 
and 2004 (Cangiano, 2010). One of these two teams also covered an area with greater 
proportions of people from ethnic minority groups, such as 25.2% of the population being 
Pakistani, 18.7% Indian and 15.3%  Black. The third team was based in an outer city area, 
which covered both affluent and deprived areas (Cangiano, 2010). The fourth team covered 
Solihull. Although their base was within the most deprived area of Solihull, overall Solihull is 
more affluent and less deprived than Birmingham, as only eight percent of Solihull falls 
within the 10th percentile of deprivation in the country, compared to 40% of Birmingham 
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(Solihull Metropolitan Borough Council, 2008). These teams were therefore thought to be 
representative of the diversity across the Birmingham and Solihull Area.  
 
Inclusion criteria were that participants must have a diagnosis of a mental health 
problem in the F20-F29 schizophrenia, schizotypal and delusional disorder cluster defined in 
the ICD-10 (World Health Organization, 1993), as determined by the participant’s 
psychiatrist. They must be on the caseload of an AOT. All participants needed to speak 
English. Exclusion criteria included being detained in a psychiatric hospital under a section of 
the Mental Health Act (2007), being acutely unwell, or being intoxicated at the time of 
interview. These criteria were in place to protect individuals who may not be able to give 
informed consent to participate.   
 
Procedure 
The research was approved by a local ethics committee and by the Research and 
Development department within the participating NHS Trust.  
Potential participants were identified by the multidisciplinary team within each AOT. 
The potential participants were approached by a member of AOT staff with whom they were 
familiar, such as their care co-ordinators. Some individuals also discussed the research with 
the researcher if the participants wished to do so. Potential participants were provided with an 
outline of the research verbally and in written format.  If the participants agreed to take part, 
an interview between the participant and researcher was arranged. 
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At the time of interview, a verbal description of the research was presented again to 
the participant, and each participant signed a consent form before the interview commenced. 
The interview took approximately one hour and consisted of standardised semi-structured 
interviews and questionnaires, dictated verbally by the researcher, that measured symptoms of 
psychosis, depression, and drug use. Individuals were assigned to ‘cannabis users’ or ‘non-
cannabis users’ depending on self disclosure of cannabis use. The degree to which cannabis 
use was problematic was also assessed. Demographic information about participants was 
collected during the interview and from computerised data held by each team. Participants 
were given £5.00 to compensate them for their time, and any costs incurred in attending the 
interview.  
 
Measures 
Three standardised measures were used during all interviews. An additional measure 
was used during the cannabis users’ interviews to assess problematic use of this substance. 
The measures used are listed below. 
 
Negative & Positive Symptoms of Psychosis: The Structured Clinical Interview for the 
Positive and Negative Syndrome Scale (PANSS; Kay, Fiszbein, & Opler, 1987). 
The PANSS is a structured interview that assesses the severity of positive symptoms, 
negative symptoms, the relationship between positive and negative symptoms, and general 
psychopathology. The symptoms are scored via verbal answers from the individual with 
psychosis and observations made by the interviewer. Additional information from 
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professionals and family members can also be integrated into the scores. There are seven 
positive symptom items, seven negative symptom items, and 16 general psychopathology 
subscales on the PANSS. Each symptom item is scored from one to seven, one being ‘absent’ 
and seven being ‘extreme’. Therefore scores for positive and negative symptoms range from 
seven to 49; general psychopathology ranges from 16 to 112; and total PANSS score ranges 
from 30 to 210. Kay, Opler, and Fiszbein (1987) calculated t scores that corresponded to raw 
scores on each subscale. A total positive score of 20 corresponded to a t-score of 50, and 
therefore this was ‘average’ compared to a group of 240 medicated people with 
schizophrenia. A total negative score of 22, a positive minus negative score of -2, and a 
general psychopathology total of 40 were also deemed to be ‘average’. Assessors must be 
experienced in working with individuals with psychosis, and additional training is required to 
use the PANSS. It was used in this research due to its previous use in cannabis and psychosis 
research (e.g. Addington & Addington, 2007; Batki et al., 2008; Bersani et al., 2002; 
Compton et al., 2004), which may aid comparison of data. The PANSS has been 
recommended for research use over the Brief Psychiatric Rating Scale (Bell, Milstein, Beam-
Goulet, Lysaker, & Cicchetti, 1992). 
The PANSS has good reliability, criterion-related validity, and predictive validity 
(Kay, Fiszbein et al., 1987). It has also been found to be sensitive to medication.  
 
Depression: The Calgary Depression Scale (CDS; Addington, Addington, & Maticka-
Tyndale, 1993). 
This brief, nine item, scale is administered in interview format. It measures depressive 
symptoms that are separate to negative and extrapyramidal symptoms, in people with 
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psychosis (Addington, Addington, & Maticka-Tyndale, 1994). This sensitivity to negative 
symptoms was the reason the CDS was used in this study. Eight items measure verbal 
feedback from interviewees, whilst observations are made by the interviewer. The ninth item 
is an overall assessment of the interviewee’s presentation. The greater the total score, out of 
27, the greater the depressive symptoms. A score of 6 or above would indicate 85% 
sensitivity and 82% likelihood of a major depressive episode. The CDS has been found to 
have high inter-rater reliability (0.895) (Addington, Addington, Matilka-Tyndale, & Joyce, 
1992).  
 
Substance Use: The Maudsley Addiction Profile (MAP; Marsden et al., 1998). 
The MAP was designed in the UK in order to assess alcohol and drug addictions. The 
questionnaire contains 60 items that assess four domains known to contribute to addictions to 
substances, which are substance use, health risk behaviour, physical and psychological health 
factors, and the individual’s social functioning. It is presented in interview format. Within this 
research, only Section B was used. This section details substance use over the previous 30 
days, and ascertains how many days the individual has used substances, how much they used 
on a typical day, and how they consumed the substance.  
The MAP was originally designed as an outcome measure for addiction treatment, but 
is very appropriate as a research tool. It has high test-retest reliability (average of 0.94 across 
different substances), as well as being easily administered (Marsden et al., 1998). 
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The MAP was used in this research not only to assess quantity and frequency of 
cannabis use, but to also collect information about other substance use, which may have 
affected current psychosis symptoms. 
 
Cannabis Dependence: The Severity of Dependence Scale (SDS; Gossop et al., 1995). 
The SDS is a brief, five question measure that assesses a person’s dependence on a 
particular substance, which is named before completion. The scale measures factors relating 
to substance dependency, such as perceived control over the use of the substance, 
preoccupation with use, and anxieties about substance-related behaviour.  
Swift, Copeland, and Hall (1998) suggested a score of three or above on the SDS 
indicated cannabis dependence in the general population. However, Hides, Dawes, Young, 
and Kavanagh (2007) reported that individuals with psychosis who scored greater than or 
equal to a total score of two on the SDS were 28.6 times more likely than people with lower 
scores to meet the criteria for cannabis dependence in the DSM-IV. They found the SDS to 
have overall accuracy of 84.3%, and high internal consistency (0.81) when used to measure 
cannabis dependence. The SDS was used in the current study to identify whether individuals 
were likely to be dependent on cannabis at the time of the research. A score of two or above 
will be used to indicate an increased likelihood of cannabis dependence, due to similarities 
between the mental health diagnoses of the current sample and that of Hides and colleagues’ 
sample.  
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Results 
Data Analysis 
In order to analyse the relationships between cannabis use, and different symptoms of 
psychosis the following statistical tests were executed. One way analyses of variance 
(ANOVAs) were used to compare the means of continuous demographic variables, such as 
age and duration of illness, in the cannabis users and non-cannabis users.  Chi-square tests for 
independence were conducted to compare categorical variables, such as gender, ethnic 
background, and diagnosis between groups. One-way ANOVAs were subsequently used to 
compare the cannabis users’ and non-cannabis users’ mean total PANSS, total negative 
symptom subscale score, total positive symptoms, composite score, and the individual 
negative symptom scores. The same analysis was applied to compare the level of depression 
in each group, by comparing the means of the total on the CDS. An Analysis of covariance 
(ANCOVA) would have been appropriate to investigate the relationship between cannabis use 
and total negative symptoms, whilst controlling for the effects of depression. However, both 
of the two conditions required for an ANCOVA, namely that the covariate must be correlated 
with the dependent variable and the covariate must be disproportionately correlated to the 
independent variable, were violated in this study. Therefore an ANCOVA would have been 
obsolete. 
Use of other substances by both the cannabis users and non-cannabis users was 
explored using descriptive statistics. Due to the small sample sizes, and the variance in sample 
sizes for specific drugs, no statistical analysis was appropriate. 
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Participants 
  Out of a total AOT caseload of 255 people across the four teams, 58 were excluded 
due to not speaking English, being acutely unwell or detained, or having a diagnosis other 
than schizophrenia, schizotypal or delusional disorder. Of the 186 eligible clients, 158 either 
declined to take part or were not approached due to teams’ concerns about engagement. Thirty 
nine participants were recruited (19.80% of eligible participants). Data from three individuals 
who used cannabis was omitted from further analysis. Two were removed due to using only 
£2.00 worth of cannabis in 30 days, and therefore were neither non-cannabis users, nor 
cannabis users who used cannabis at least once a week. One other was removed as their data 
was deemed unreliable. 
Of the 36 remaining participants, 83.3% were male, and the mean age of participants 
was 45.61 years, ranging from 27 to 73 years. Individuals had diagnoses of schizophrenia 
(86.1%) or schizoaffective disorder (13.9%). Demographics are described in Table 1.  
There were no significant differences between the cannabis users and non-cannabis 
users in age (F=1.590, p=0.375) duration of illness (F=0.061, p=0.807) diagnoses (X2=1.536, 
p=0.215) gender (X2=0.000, p=1.000) or ethnic background (X2=3.413, p=0.332). The age of 
nonusers included three outliers. However, there was no significant difference found between 
the age of the cannabis users and nonusers with these outlier included. Due to this non-
significant difference, and taking the limited sample size into account, these outliers were 
included in all further analyses.  
Tests of normality were run on continuous variables. Duration of illness was normally 
distributed for cannabis users (K-S=0.168, p=0.200) and non-cannabis users (K-S=0.119, 
p=0.200), and age was normally distributed for cannabis users (K-S=0.129, p=0.200) but not 
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for the age of non-cannabis users (K-S=0.235, p=0.005). Due to the latter finding, and the 
non-idealised normality of the other demographics, nonparametric tests were run on all 
demographics to ascertain whether further analysis would require parametric or 
nonparametric testing. These Kruskal-Wallis analyses also found no significant difference 
between groups on age (H=0.244, p=0.621) and duration of illness (H=0.004, p=0.949). 
Therefore the cannabis users and the non-cannabis users are comparable on the demographic 
variables of age, duration of illness, gender, and ethnic background. It was concluded that 
further analysis should continue using ANOVAs due to their more robust nature compared to 
the nonparametric test (Kruskal-Wallis), and because each dependent variable showed a 
normal distribution for the cannabis users and the non-cannabis users. Kruskal-Wallis results 
are documented for the comparison of individual negative symptom items, when these were 
found to violate normality.  
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Table 1  
Characteristics of the sample 
      Total (n= 36) 
Cannabis Users 
 (n= 16) 
Non Users  
(n= 20) 
 
P (sig) 
Gender  Male   30 (83.3%)  13 (81.3%)  17 (85%)   
   Female   6 (16.7%)  3 (18.8%)  3 (15.0%)  1.000 (NS) 
Age  Years (SD)  45.61 (10.40)  43.19 (8.44)  47.55 (11.58)   
  Age range in years  27 – 73  27 – 55  34 – 73   0.375 (NS) 
Ethnicity  White   17 (47.2%)  7 (43.8%)  10 (50.0%)   
   Mixed   2 (5.6%)  1 (6.3%)  1 (5.0%)   
   Asian   3 (8.3%)  0 (0%)  3 (15%)   
   Black   14 (36.0%)  8 (50.0%)  6 (30.0%)  0.332 (NS) 
Diagnosis  Schizophrenia  31 (86.1%)  12 (75.0%)  19 (95.0%)   
   Schizoaffective Disorder  5 (13.9%)  4 (25%)  1 (5%)  0.215 (NS) 
Illness  Months (SD)  220.86 (108.49)  215.81 (96.36) 
224.90 
(119.64) 
 
0.807 (NS) 
Duration  Duration range in months  51 – 492  83 – 372  51 – 492    
PANSS  Positive symptom total (SD)  15.03 (4.37)  16.00 (4.10)  14.25 (4.53) 
 
0.238 (NS) 
   Negative symptom total(SD)  14.33 (4.99)  13.13 (2.99)  15.30 (6.05) 
 
0.238 (NS) 
   Positive  ‐ Negative  (SD)  0.69 (6.30)  2.88 (4.02)  ‐1.05 (7.29) 
 
0.049* (S) 
   General (SD)  29.11 (6.19)  29.38 (7.36)  28.90 (5.27) 
 
 
0.823 (NS) 
  Total PANSS score (SD)  58.47 (11.95)  58.50 (12.20)  58.45 (12.06) 
 
0.990 (NS) 
  N1 Blunted Affect (SD)  1.31 (0.86)  1.31 (0.79)  1.30 (0.92) 
 
0.787 (NS) 
  N2 Emotion Withdraw (SD)  1.47 (1.00)  1.38 (0.81)  1.55 (1.15) 
 
0.883 (NS) 
  N3 Poor Rapport (SD)  1.83 (1.40)  1.69 (0.95)  1.95 (1.70) 
 
0.738 (NS) 
  N4 Social withdrawal (SD)  2.28 (1.47)  2.06 (1.39)  2.45 (1.54) 
 
0.430 (NS) 
  N5 Diff. abstract think (SD)  3.61 (1.71)  3.37 (1.50)  3.80 (1.88) 
 
0.467 (NS) 
  N6 Lack of spontaneity (SD)  2.08 (1.50)  1.56 (0.81)  2.50 (1.79) 
 
0.136 (NS) 
  N7 Stereotyped think (SD)  1.75 (1.16)  1.75 (1.07)  1.75 (1.25) 
 
0.897 (NS) 
CDS  Total (SD)  3.28 (3.44)  3.50 (3.81)  3.10 (3.19) 
 
0.734 (NS) 
  Range  0 – 13   0 – 13   0 – 13    
* Asymptotically F and corresponding p according to Welch and Brown-Forsythe test, due to lack of 
homogeneity on this variable 
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Psychosis Symptoms 
 Total severity of symptoms 
There was no significant difference between the total PANSS scores for cannabis 
users and non-cannabis users (F=0.000, p=0.990). The entire range of symptoms measured by 
the PANSS was experienced by cannabis user group and the non-cannabis using group, 
except for two general scales. ‘Motor retardation’ and difficulties with ‘Mannerisms and 
postering’ were not experienced by any of the cannabis users.  
 
Severity of positive symptoms 
There was no significant difference between the total positive symptom score on the 
PANSS between the cannabis users, and non-cannabis users (F=1.442, p=0.238). The mean 
score for both groups were within the ‘slightly below average’ range compared to a group of 
medicated people with schizophrenia, according to Kay, Opler, and colleagues (1987).  
 
 Severity of negative symptoms 
No significant difference at (p>0.05) was found between the total PANSS negative 
symptom score for the cannabis users and the non-cannabis users (F=1.727, p=0.198). The 
mean scores for both groups were in the ‘below average’ range compared to medicated 
individuals with schizophrenia.   
To investigate whether different types of negative symptoms were experienced by the 
two groups further analysis was conducted on the individual items in the negative symptom 
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subscale. No significant differences were found between the groups on blunted affect 
(H=0.073, p=0.787), emotional withdrawal (H=0.022, p=0.883), poor rapport (H=0.112, 
p=0.738), passive/apathetic social withdrawal (H=0.622, p=0.430), difficulties with abstract 
thinking (F=0.541, p=0.467), lack of spontaneity (H=2.220, p=0.136), or stereotyped thinking 
(H=0.017, p=0.897). The negative symptom that was least experienced was ‘blunted affect’ 
for both cannabis and non-cannabis users, and the more severe was ‘difficulty in abstract 
thinking’. 
As can be seen in table 1, the composite subscale that shows the prominence of 
symptom types, by deducting the positive subscale total from the negative subscale total, 
shows borderline significance (F(30.562)=4.200; p=0.049). As can be seen by the df value, the 
Welch and Brown- Forsyth test results have been reported as these tests control for the 
unequal variance found within the groups on this variable. As the result is very close to the 
cut off point for significance, the null hypothesis should be favoured. However it does show 
that cannabis users were more likely to have predominant positive symptoms than negative 
symptoms, and the non-users were likely to have more severe negative symptoms than 
positive symptoms. 
 
Depression 
No significant difference was found between mean total CDS scored for cannabis 
users and non-cannabis users (F=0.117 p=0.734). The mean scores for both groups suggested 
that it is unlikely that the groups, on average, were experiencing major depression. Four 
individuals (25%) in the cannabis using group, and four (20%) of the non-cannabis using 
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group, obtained a score of 6 or more on the CDS, and therefore these individuals were likely 
to have been experiencing a major depressive episode.  
 
Substance Use 
 Cannabis use 
The quantity of money spent on cannabis was taken as a measure of quantity of 
cannabis use. As can be seen from Table 2 there was substantial heterogeneity in the levels of 
cannabis use, ranging from £8.00 to £300.00 during 30 days. Out of the 16 cannabis users, 8 
(50.0%) scored two or greater on the SDS, and therefore were more likely to meet the DSM-
IV criteria for cannabis dependence. Only two cannabis users were using no other substances.  
 
Other substance use  
As can be seen in Table 2, 27 (75.0%) of the total study sample used at least one 
substance, and 22 (61.1%) used at least one illicit substance. Nobody in either group reported 
using illicit methadone, or illicit benzodiazepines. The majority of non-cannabis users 
(65.0%) used substances. Fourteen of the 16 (87.5%) cannabis users used at least two 
substances, whilst 4 (20.0%) of the non-cannabis users were polysubstance users. The 
substance used by the most people, and most frequently in the non-cannabis group was 
alcohol (n=7; 10.86 days), then crack cocaine (n=6; 10.50 days), then heroin (n=4; 9.25 days), 
although the difference between frequencies is less than one day. The cannabis non-using 
group spent more money on crack cocaine (£306.67) than heroin (£87.50) in thirty days.  
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In the cannabis using group, the substance used by most people, after cannabis, was 
alcohol (n=12), then cocaine (n=5), followed by heroin (n=1), and amphetamines (n=1). 
Cannabis was used more frequently (10.00 days), then alcohol (7.58 days), then cocaine (6.20 
days) with one participant using heroin on two days, and another participant using 
amphetamines once in a thirty day period.  
Nineteen participants in the total sample reported using alcohol, 12 cannabis users and 
seven non-cannabis users. The quantity of alcohol consumed in thirty days showed wide 
variation, ranging from 7.20 – 122.00 units for cannabis users and 1.30 to 480.00 for non-
cannabis users. The mean consumption of alcohol was much higher in the cannabis non-using 
group at 134.19 units, compared to 36.80 units for the cannabis using group. 
Crack Cocaine was used by 11 participants in the total sample. The proportions of 
crack cocaine users were similar in the two groups (31.3% of cannabis users; 30.0% of non- 
cannabis users). However crack cocaine was used more frequently by non-cannabis users 
(10.50 days) than cannabis users (6.20 days). Non-cannabis users also spent much more 
money on it (£306.67) than cannabis users (£182.00). Again the quantities used by different 
participants in the total sample varied greatly, from between £30.00 and £1200.00 in thirty 
days.   
Five people from the total sample used heroin. Heroin was used by more non-cannabis 
users (20.0%) than cannabis users (6.3%), and much more money was spent on heroin on 
average by non-cannabis users (£87.50) than the one cannabis user (£8.00).  The money spent 
by the non-cannabis users ranged from £10.00 to £300.00 during thirty days. 
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Table 2 
Substance use in the previous 30 days 
    Total Cannabis users  Non‐cannabis users
Substances  Use 1 substance (excl cannabis) 27 (75.0%) 14 (87.5%)  13 (65.0%)
  Use 1 substance (excl alcohol) 22 (61.1%) 16 (100.0%)  6 (30.0%)
  Use 2+ substances   18 (50.0%) 14 (87.5%)  4 (20.0%)
  Number of people using (%) 19 (52.7%) 12 (75.0%)  7 (35.0%)
Alcohol 
units on typical day (SD)  
Range 
6.13 (4.38)
1.30 – 16.00 
5.51 (3.47) 
2.20 – 15.30 
7.20 (5.77)
1.30 – 16.00 
  
Number of days used (SD)  
Range 
8.79 (9.29)
1 – 30  
7.58 (6.32) 
2 – 20  
10.86 (13.34)
1 – 30 
 
Total units in 30 days (SD) 
Range 
72.68 (127.21)
1.30 – 480.00 
36.80 (35.23) 
7.20 – 112.00  
134.19 (198.21)
1.30 – 480.00 
  Number of people using (%) 5 (13.9%) 1 (6.3%) 4 (20.0%)
 Heroin 
 £ on typical day. (SD)  
Range 
7.80 (3.03) 
 
4.00 
 
8.75 (2.50) 
5.00 – 10.00 
  
Number of days used (SD) 
Range 
7.80 (12.46)
1 – 30  
2.00
 
9.25 (13.89)
1 – 30  
  Total in £ in 30 days (SD) Range 
71.60 (127.80)
8.00 – 300.00 
8.00
 
87.50 (141.75)
10.00 – 300.00 
  Number of people using (%) 11 (30.6%) 5 (31.3%) 6 (30.0%)
 Crack Cocaine 
£ on typical day. (SD)  
 Range 
30.91 (27.461)
5.00 – 100.00 
35.00 (37.75) 
10.00 – 100.00 
27.50 (18.37)
5.00 – 50.00  
  
Number of days used (SD) 
Range 
8.55 (7.69)
1 – 30  
6.20 (2.28) 
4 – 9  
10.50 (10.19)
1 – 30  
 
£ in 30 days. (SD) 
Range 
250.00 (338.17)
30.00 – 1200.00 
182.00 (150.73) 
60.00 – 400.00  
306.67 (449.52)
30.00 – 1200.00 
  Number of people using  1 (2.8%) 1 (6.3%) 0
 Amphetamines  £ on typical day.  20 20 0
   Number of days used  (SD) 1 1 0
  
 
£ on typical day. (SD)  
Range 
7.69 (4.50)
2.00 – 20.00 
7.69(4.50) 
2.00 – 20.00  0 
 Cannabis 
Number of days used (SD) 
Range 
10.00 (10.73)
2 – 30  
10.00 (10.73) 
2 – 30   0 
 
£ in 30 days. (SD)  
Range 
84.44 (109.99)
8.00 – 300.00 
84.44 (109.99) 
8.00 – 300.00  0 
  SDS total  (SD) Range.  2.00 (2.37) 0 – 8  2.00 (2.37) 0 – 8   0
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Discussion 
All the participants in this study were people who had lived with schizophrenia or 
schizoaffective disorder for an average of 220.86 months (18.4 years). The results indicated 
that they were currently experiencing the whole range of negative and positive symptoms. 
Although the age of the total sample ranged from aged 27 to 73 years, the mean age was 
45.61 years old. The CDS scores suggest that the majority of the sample were unlikely to be 
experiencing a major depressive episode at the time of interview. A surprising finding of this 
study was the amount of substance use across the total sample, as 75% used at least one 
substance other than cannabis, and 61.1% of the total sample were using illicit substances. 
Polysubstance prevalence was found to be as high as 50.0% in the total sample. The 
prevalence of substance use in this study exceeds the amount of substance abuse found in 
another AOT sample by Graham and colleagues (2001), which was between 26 and 45%. In 
the current study, there was also an unexpected amount of substance use reported by the non-
cannabis users. Whilst 87.5% of cannabis users used other substances, 65.0% of non-cannabis 
users also used substances. The people in the non-cannabis using group who used alcohol, 
crack cocaine, or heroin, used them more frequently and used greater amounts than the people 
using cannabis.  
With regards to symptoms, the results show that there was no significant difference 
between the negative symptoms, and indeed positive symptoms, experienced by people who 
were using cannabis and those who were not. The hypotheses, therefore, were not supported. 
The results were in contrast to research that found fewer negative symptoms in cannabis users 
or misusers (Bersani et al., 2002; Compton et al., 2004; Dubertret et al., 2006). However, it 
was in line with other literature that also found no association between negative symptoms 
and cannabis use or misuse (Addington & Addington, 2007; Boydell et al., 2007; Grech et al., 
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2005). Slightly greater levels of positive symptoms were experienced by individuals using 
cannabis compared to non-cannabis users, but this was as small as two points on the PANSS.  
This small difference may be indicative of the suggestion by Hides and colleagues (2006) that 
cannabis users experience greater positive symptoms, which may then contribute to greater 
cannabis use. There was also a tendency for cannabis users to experience less severe negative 
symptoms than cannabis non-users, but again this was only a two point difference on the 
PANSS. Whilst these results failed to meet significance, they were trends in the direction 
found by earlier research (Bersani et al., 2002; Compton et al., 2004; Dubertret et al., 2006).   
There seem to be three factors that may account for no significant difference being 
found between the negative symptoms experienced by cannabis users and non-cannabis users. 
These are the sample size of the current study; the historical profile of substance use; and the 
use of other substances by cannabis users and cannabis non-users.  
The sample size in this study was smaller than the sample in Bersani and colleagues’ 
(2002) study (n=125), Dubertret and colleagues’ (2006) study (n=205), and Batki and 
colleagues’ (2008) study (n=80).  It may be argued, therefore, that the sample was not large 
enough to find any significant difference between the negative symptoms being experienced 
by cannabis users or non-cannabis users. The sample size in the current research, however, 
was greater than the sample size in Compton and colleagues’ study (n=18) who did find 
significantly lower negative symptoms in cannabis misusers. Studies that did not find the 
association between cannabis and negative symptoms contained 203, 757, and 97 people 
(Addington & Addington, 2007; Boydell et al., 2007; Grech et al., 2005) respectively. 
Therefore it is unlikely that a small sample size is the only reason why no association was 
found between negative symptom severity and cannabis in the current study.   
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The second factor that is hypothesised to contribute to the lack of association between 
negative symptoms and cannabis use may be that only current substance use was assessed. 
Therefore, these results do not take into account the course of cannabis use, or indeed the 
course of negative symptoms experienced throughout the illness duration. Therefore, 
observations such as earlier onset of negative symptoms being found amongst cannabis users 
(Veen et al., 2004), or cannabis use at the time of illness onset being associated with less 
negative symptoms during the illness (Dubertret et al., 2006) could not be assessed in the 
current sample. 
The third factor that may account for no association being found between cannabis use 
and negative symptoms is the extent of other substance use and poly-substance use, including 
a number of Class A drugs, found within both cannabis and non-cannabis users. Whilst more 
cannabis users (75.0%) used alcohol than non-cannabis users (35%), more non-cannabis users 
used heroin (20%) than cannabis users (6.3%), and similar number of cannabis users (31.3%) 
and non-cannabis users (30%) used crack cocaine. For those who used these substances, the 
non-cannabis users used greater amounts of alcohol, crack cocaine, and heroin than cannabis 
users.  
The levels of substance use in the non-cannabis using group have not been observed in 
other cannabis/symptom research. Studies that have documented other substance use found 
that alcohol and cocaine (Batki et al., 2008; Compton et al., 2004), alcohol and opiates 
(Dubertret et al., 2006), alcohol, hallucinogens, opiates, and stimulants (Bersani et al., 2002), 
alcohol, amphetamines, and hallucinogens (Addington & Addington, 2007) and opiates, 
cocaine, hallucinogens, glue and stimulants (Grech et al., 2005) were being used. The 
majority of these studies discussed substance use across the total sample, and did not identify 
or differentiate the use of substances in the cannabis and non-cannabis using groups 
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(Addington & Addington, 2007; Batki et al., 2008; Grech et al., 2005). Dubertret and 
colleagues (2006) found that their cannabis misusers were nearly five times more likely to be 
misusing other substances, particularly alcohol and opiates, than the group who did not 
misuse cannabis. Similarly, Peralta and Cuesta (1992) found greater misuse of other 
substances by their cannabis users (52%) than their non-cannabis users (11%). Compton and 
colleagues (2004) found alcohol or cocaine dependence in 37.5% of their cannabis users, 
compared to no dependence in the ‘non-cannabis dependent’ group, but 60% of this group 
met criteria for cannabis or alcohol abuse. Therefore Compton and colleagues’ research is not 
comparable to the cannabis users or non-cannabis users in the current study. Bersani and 
colleagues (2002) found that their cannabis users and non-cannabis users showed no 
significant difference in other substance use, as 26% of cannabis users, and 27% of non-
cannabis users used alcohol, and 11% of cannabis users, and 13% of non-cannabis users used 
tranquilisers. Therefore, it may be that the use of different types, and amounts, of substances 
may have confounded results, and may be responsible for some of the variance found across 
studies. The high prevalence of substance use in the current research may explain some of the 
incongruence in results compared to Bersani and colleagues, Peralta and Cuesta, and 
Dubertret and colleagues, who all found less polysubstance use in their samples.  
The question remains as to what effect the other substances may have had on negative 
symptoms. Heroin has been reported to have antipsychotic properties (Pacini & Maremmani, 
2005), and therefore may reduce positive and negative symptoms. However, opiates have also 
been found to increase negative symptoms (Dixon et al., 1990). Past or current cocaine misuse 
has been associated with fewer negative symptoms than those who had no history of 
substance abuse (Lysaker, Bell, Beam-Goulet, & Milstein, 1994), but again, others found no 
such correlation (Sevy, Stanley, Opler, & van Praag, 1990). Both heroin (Tanda, Pontieri, & 
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Di Chiara, 1997) and cocaine (Kreek, 1996) affect the same neurological pathway, namely the 
dopamine pathway, as cannabis, which may partially explain why more people who were in 
the non-cannabis using group were using more heroin and cocaine. 
Alcohol consumption has also been found to decrease when the antipsychotic 
Clozapine is introduced (Drake, Xie, McHugo, & Green, 2000), which may link alcohol use 
with attempts to alleviate symptoms. Alcohol and cannabis may have similar effects on 
individuals as they are both depressants, but are both perceived by substance abusers, along 
with cocaine, to relieve depression and help them relax (Dixon et al., 1991).   
Only two studies dissected their samples to analyse ‘pure’ cannabis users compared to 
non-users of any substances. Dubertret and colleagues (2006) found that ‘pure’ cannabis users 
experienced significantly less avolition-apathy than people using no substances. In contrast, 
Bersani and colleagues (2002) found that there was no significant difference between negative 
symptoms experienced by ‘pure’ cannabis users and those not using any substance, but 
polysubstance users showed significantly fewer negative symptoms compared to the ‘pure’ 
cannabis users. Unfortunately, in the current study ‘pure’ cannabis users could not be 
compared to non-substance users because there were only 2 people (12.5%) and 7 people 
(35%) who would fit these categories respectively. Therefore the role of cannabis in negative 
symptom severity is unclear in the current study, due to other substance use being so 
prevalent. 
The absence of cannabis use in the cannabis non-using group may be due to cannabis 
being replaced by other substances. The ‘gateway theory’ (Kandel, 1975) of substance use 
suggests substances are used in a specific order. It is theorised that alcohol use occurs first, 
then tobacco, and then cannabis. Cannabis is then proposed as a ‘gateway’ drug, in that its use 
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increases the likelihood that other ‘harder’ drugs, such as cocaine and heroin might be used. 
Although participants in the current sample were suitably assigned to the ‘non-cannabis using 
group’ at the time of interview, it is possible that these individuals may have used cannabis in 
the past, and have consequently moved on from using cannabis to using the ‘harder drugs’, 
heroin and cocaine. However, the pattern of lifetime substance use was not collected so this 
cannot be confirmed in the current study.  
  The severity of negative symptoms experienced by both the cannabis and non-
cannabis users was assessed as ‘below average’ on the PANSS. It has been hypothesised that 
substances may not affect symptoms, but rather symptoms influence access to substances. 
That is, people with less negative symptoms are more socially able, and consequently are able 
to go out and obtain drugs (Mueser et al., 2000). This hypothesis is not disputed within this 
research, as both the cannabis and non-cannabis indicated ‘below average’ levels of negative 
symptoms, and both groups were obtaining illicit substances.  However, there may be other 
reasons for the finding of ‘below average’ symptoms.  
The ‘below average’ negative symptoms may be due to symptoms being treated 
effectively, by the AOTs, with medication, psychological therapies and social engagement 
opportunities. Another possibility may be that the medicated individuals with schizophrenia 
that the t scores and classifications were based on (Kay, Fiszbein et al., 1987) were different 
to this Assertive Outreach population. The PANSS was developed in 1987 and therefore the 
medication that the normative sample was likely to have received may differ to medication 
available today. They were also inpatients from long-term psychiatric units, which differs 
from the community sample in this study. Perhaps therefore the ‘below average’ scores found 
in the normative sample in 1987 differ from what would be deemed ‘below average’ for the 
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current AOT sample, and indeed other recent research samples where the PANSS has been 
used.  
 
Limitations 
Less than 20% of the eligible service users in the AOTs agreed to take part in the 
current research. It was speculated that perhaps individuals who were experiencing the most 
severe negative symptoms may have declined to take part, as some degree of motivation was 
required to attend the interview. Individuals who were acutely unwell and required detention 
in hospital were excluded due to consent issues and therefore this population was not 
represented in the current study. Therefore the research sample may not have represented all 
individuals being cared for by AOTs.  
A methodological limitation to the design was that the assessments were conducted by 
the author, who knew participants’ group allocation. However, no statistical analysis was 
conducted until all data had been collected so as to restrict observations of any patterns 
emerging within groups.  Participants were not informed of the research hypotheses before 
participation, and therefore their responses were unlikely to have been altered by desires to 
give correct answers. However a potential bias is that people with mental health difficulties, 
such as schizophrenia, may have been suspicious about disclosing information to a stranger 
about their mental health and about illicit substance use. Urine testing has been used in other 
research to detect the use of substances, but this would not have provided information about 
quantities and frequencies of use.   
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Information regarding current medication regimes was not collected. If medication 
type or dosage differed between the cannabis users and non-cannabis users, this may have 
affected the symptoms found within each group.  
The total sample represented a large variety of ages, and durations of illness. Although 
there was no difference between the two groups on these two variables, interactions between 
cannabis and age, or cannabis and chronicity of illness could not be analysed due to the small 
sample size. In future studies with larger samples, it may be possible to stratify groups due to 
age and illness duration to assess any interactions of these variables with symptoms and 
cannabis use. As previously mentioned, the trajectory of cannabis use, and other substance 
use, should be investigated further, giving special attention to the onset of cannabis use and 
the onset of illness.  
 
Conclusion 
This research suggests that the negative symptoms, and indeed positive symptoms that 
are experienced by people who use cannabis alongside other substances, are not significantly 
different to the symptoms experienced by people who do not use cannabis, but may use other 
substances. As high levels of substance use for people who are under the care of AOT have 
been replicated in this study, it seems important that all substance use is considered whilst 
formulating people’s psychosis symptoms, functioning, current difficulties and delivering 
treatment. Due to the surprising amounts of substances being used by people who are not 
currently using cannabis, it may be useful in further research to assess the impact of different 
substances on symptoms, daily functioning, and further substance use. Further research is also 
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required to investigate the trajectory of substance use before and throughout the course of 
schizophrenia and schizoaffective disorder.  
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Introduction 
 
Symptoms of schizophrenia and related disorders are often split into two groups, 
‘positive symptoms’ and ‘negative symptoms’. Positive symptoms include experiences that 
most people do not have, such as hallucinations and delusions. ‘Negative symptoms’ 
described things that have been lost because of the schizophrenia, such as motivation or 
pleasure. As negative symptoms have been linked to poorer outcome (e.g. Siegel et al., 2006) 
treatment of these symptoms is important in order to improve individuals’ mental health and 
daily functioning. Other factors that are linked to poorer functioning, such as cannabis use, 
should also be researched in order to find out if they have an effect on negative symptoms.  
 
Literature Review 
The National Institute of Clinical Excellence (2009) recommended psychological 
therapies, and in particular cognitive behavioural therapy (CBT) and family interventions, for 
the treatment of schizophrenia. However, other psychological therapies have also been 
conducted in order to alleviate symptoms of schizophrenia and related disorders, such as 
cognitive remediation therapy (CRT), and body-oriented psychological therapy (BPT).  
Literature published in the last 11 years suggests that all four of these psychological therapies 
can improve negative symptoms. Also, the improvements found following CBT could last up 
to five years. Different therapies appeared to effect different negative symptoms, such as BPT 
improving slowed movements and flattened mood, whilst family interventions increased 
motivation and improved social interactions. Out of the four psychological therapies, 
individual sessions of CBT were the most consistent at improving negative symptoms.  
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Research Study 
Cannabis has been found to be the second most commonly used substance, after 
alcohol, in people with severe mental health problems (Graham & Maslin, 2002). The effect 
of cannabis on negative symptoms remains uncertain, as some research has found no link 
between the two (e.g. Addington & Addington, 2007), and some have found less negative 
symptoms in people using cannabis (e.g. Bersani et al., 2001). Depression often occurs 
alongside schizophrenia, and can be mistaken for negative symptoms. This research was 
conducted to see whether severity of negative symptoms differs for cannabis users compared 
to non-cannabis users, who are under the care of Assertive Outreach Teams (AOTs). It also 
addressed whether cannabis use, depression, and negative symptoms occur together. 
 
Participants 
The 39 participants were people who had schizophrenia or schizoaffective disorder, 
and who were under the care of four AOTs. The average age for the total sample was 45.61 
years old, and 83.3% were men. There was no difference in age, gender, ethnicity, diagnoses, 
or illness duration between people who used cannabis and those who did not.  
 
Method 
The participants attended one interview with the researcher, in which mental health 
and depressive symptoms were assessed using structured interviews. The participants were 
also asked about the substances that they had used in the last thirty days. If they stated that 
they had used cannabis at least once per week in the 30 day period, they were allocated to the 
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‘cannabis using’ group (16 people). If they had not used cannabis at all, they were allocated to 
the ‘non-cannabis using’ group (20 people). Dependence on cannabis was also assessed. The 
mental health symptoms, depressive symptoms, and other substance use were then compared 
between the cannabis users and the non-cannabis users.   
 
Results 
• There were no significant differences between the severity of negative symptoms, or 
positive symptoms experienced by people using cannabis and those not using 
cannabis. Both groups experienced ‘below average’ levels of negative symptoms 
compared to medicated inpatients with schizophrenia.  
• There was no significant difference in the levels of depressive symptoms experienced 
by people using cannabis and those who were not.  
• The majority of cannabis users and non-cannabis users were using others substances. 
 
Conclusions 
 The results were similar to those found in studies of people in their first episode of 
psychosis, but differed from those found in people who had had the illness for longer than one 
episode. These unexpected findings may be due to three factors: the sample may not have 
been large enough to dictate a difference; past substance use may affect current symptoms and 
past drug use was not assessed in this study; and the quantity of other drugs being used by 
both the cannabis users and the non-cannabis users may have affected symptoms. 
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 This study found very high levels of substance use in people under the care of AOTs, 
even when some of these people were not using cannabis. As both cannabis use, other 
substance use, and negative symptoms have been linked to poorer outcome in schizophrenia 
and related disorders, interactions between each substance and negative symptoms need to be 
researched. Substance misuse and negative symptoms need to be addressed during mental 
health treatment for people under the care of AOTs.  
 
References 
Addington, J., & Addington, D. (2007). Patterns, predictors and impact of substance use in 
early psychosis: a longitudinal study. Acta Psychiatrica Scandinavica, 115, 304-309. 
Bersani, G., Orlandi, V., Kotzalidis, G.D., Pancheri, P. (2002). Cannabis and schizophrenia: 
impact on onset, course, psychopathology and outcomes. European Archives of 
Psychiatry and Clinical Neuroscience, 252, 86-92.  
Graham, H.L., & Maslin, J. (2002). Problematic cannabis use amongst those with severe 
mental health problems in an inner city area of the UK. Addictive Behaviours, 27, 
261-273.  
National Institute for Health and Clinical Excellence (2009). Schizophrenia: Core 
 interventions in the treatment and management of schizophrenia in adults in primary 
and secondary care. (Clinical Guideline 82). Retrieved December 6 2009, from 
http://www.nice.org.uk/nicemedia/pdf/CG082quickrefguide.pdf 
Siegel, S.J., Irani, F., Brensinger, C.M., Kohler, C.G., Bilker, W.B., Ragland, J.D. et al. 
(2006). Prognostic variables at intake and long-term level of function in 
schizophrenia. American Journal of Psychiatry, 163, 433-441. 
107 
 
     
108 
 
 
 
 
 
 
APPENDICES 
     
 
 
 
 
 
APPENDIX 1 
LETTER FROM THE LOCAL ETHICS COMMITTEE 
  
109 
 
     
 
110 
 
     
 
111 
 
     
112 
 
     
 
113 
 
     
 
 
 
 
 
APPENDIX 2 
PARTICIPANT INFORMATION SHEET 
114 
 
     
Version 2 
18/03/2009    
Participant Information Sheet 
 
Negative Symptoms in people who experience psychosis, 
and use cannabis 
 
I would like to invite you to take part in a research study that is looking at the symptoms 
experienced by people with a diagnosis of psychosis, and who do, or do not use cannabis. 
Before you decide if you would like to take part, you need to know why the research is being 
done, and what you would need to do. Please read this information sheet, which explains the 
research fully. If you have any questions, or would like more information, feel free to talk to 
me or a member of your care team about the research. Part 1 explains why the research is 
being done, and what would be involved in taking part. Part 2 explains how the research will 
take place.  
Part 1 
What is the purpose of the study? 
This research intends to find out whether people who have psychosis and use cannabis 
experience different negative symptoms than those who do not use cannabis. Negative 
symptoms include loss of motivation, reduced emotional responses, decreased thought 
processes, reduced enjoyment in activities, and social withdrawal. It is important to look at 
these symptoms because they might feel uncomfortable and might stop people from living the 
full life that they would like to.  
The study also intends to look at whether negative symptoms and depression occur together in 
people under the care of Assertive Outreach Services. This information may help the 
Assertive Outreach Teams to care for all the different difficulties that people may be facing if 
they experience negative symptoms as part of their psychosis.   
Why have I been invited? 
Your Consultant Psychiatrist or care-coordinator in Assertive Outreach has put your name 
forward as somebody who might like to take part in this research. You have been invited to 
take part because you have been given a diagnosis that fits under the term ‘psychosis’. These 
diagnoses include schizophrenia, schizotypal and delusional disorders. You also access 
Assertive Outreach Services, and you are able to understand English fluently enough to take 
part in an interview about your diagnosis and your drug use.  
Do I have to take part? 
No, you do not have to take part in the study. It is up to you to decide. I will describe the 
study to you now, and then give you this information to look through in your own time. You 
can then tell a member of your care team if you would like to take part or not. If you do want 
to take part, they will tell the researcher, and I will contact you to arrange an interview. You 
are free to withdraw at any time until all of your information has been collected and analysed. 
You do not have to give a reason for withdrawing. Taking part, or deciding not to take part in 
the research will not affect the care that you receive from the Assertive Outreach Team. 
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What will happen to me if I take part? 
If you decide to take part, the researcher will arrange to meet with you in order to conduct an 
interview. This interview will last approximately one hour and will usually take place at the 
Assertive Outreach Team offices. In the interview, the researcher will ask you some questions 
which will look at your mental health, behaviour, lifestyle, mood, and possible drug use. 
Everyone who takes part in the research will be asked the same questions.  
The researcher will also ask for your permission to look at some of your information at the 
Assertive Outreach Team. This information will come from the FACE: Health and Social 
Assessment Scale, which is the interview that is done with your care-coordinator roughly 
every 6 months. The researcher will only be looking at information that is relevant to the 
research. 
When the FACE information has been collected and the interview has taken place, your 
information will be put together with other people’s answers, and then analysed using a 
computer program. The results will be shown for a group of people who do use cannabis and 
a group of people who do not use cannabis. No individual information will be reported. 
Expenses and Payments 
Taking part in the research may require you to travel for the interview, and will take one hour 
of your spare time. We can, therefore, offer you £5.00 to cover any expenses and to 
compensate for your time, when you attend the interview.  
What are the possible disadvantages and risks of taking part? 
If you decide to take part you are going to be asked to discuss your mood, mental health, 
lifestyle, and any drugs that you have used. It may be uncomfortable or upsetting to talk about 
some of these things. If you feel upset during the interviews, or do not want to discuss 
anything that you are asked about, you have the right to stop the interview at anytime, or to 
withdraw from the research. If you would like to talk to somebody about any upset caused, 
your Assertive Outreach Team will be able to support you. 
What are the potential benefits of taking part? 
We cannot promise that your care will change as a result of taking part in this study. 
However, the information that we get from this study may help to improve the recognition of 
certain symptoms, and how cannabis use might affect these symptoms in psychosis. 
What happens when the research stops? 
The care you get from the Assertive Outreach team will not be affected by taking part in this 
study. After the study, your care will continue as it did before and during the study.  
What if there is a problem? 
If you are unhappy when you are taking part in the study, you can withdraw from it. Any 
complaints or issues that you may have about the study will be addressed by Dr Brendan 
Laverty, Assistant Director of Research and Commercial Services at the University of 
Birmingham. Further details will be given in Part 2 of this leaflet.  
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Will my taking part in the study be kept confidential? 
The only people who will be aware that you are taking part in this study will be the researcher 
who is doing the interview with you, your Consultant Psychiatrist, and your care-coordinator 
within the Assertive Outreach Team. Your Consultant Psychiatrist and care-coordinator will 
not be told about the answers that you give. However, if you begin to feel distressed you may 
choose to talk to a member of the Assertive Outreach Team about this. The researcher will 
inform the Assertive Outreach Team if you mention anything that suggests that you or 
anybody else is at risk of harm. Any personal drug use that you talk about in the interview 
will not be reported to the Assertive Outreach Team.  
When you are giving your answers, they will be written down. However, no-one except the 
researcher will be able to identify that they are your answers because all questionnaires will 
have an identifier code on them, and not your name. The information that is put on the 
computer for analysis will only include the identifier code, and will be password protected, so 
only the researcher can access it.  
 
Part 2 
What if relevant new information becomes available? 
If any new information that affects the study becomes available the researcher will let you 
know. If the study is stopped the researcher will tell you. 
What will happen if I don’t want to carry on with the study? 
You are able to withdraw from the study at any time up to the data analysis.  If you decide to 
withdraw, we may ask for your permission to use the information that has been collected up 
to that point. It is your right to say no to this. All information that has been collected will be 
destroyed if it is not being used in the study. 
What if there is a problem? 
If you have any concerns about the research, you can speak to Dr Brendan Laverty, Assistant 
Director of Research and Commercial Services at the University of Birmingham. His contact 
details are as follows: 
 Dr Brendan Laverty,  
Assistant Director of Research and Commercial Services 
Aitchison Building 
University of Birmingham 
Edgbaston 
Birmingham 
B15 2TT 
Telephone: 0121 4147618.  
 
In the event that you are harmed during the study due to someone’s negligence, then you may 
have the grounds for a legal action for compensation against the University of Birmingham or 
the National Health Service Trust. 
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What will happen to the results? 
The results from all of the participants will be analysed together. The answers given by people 
who use cannabis will then be compared to the answers given by people who do not use 
cannabis.  
A brief written summary of the study will be given to each participant. Participants who do 
not read will have the summary read to them during a routine weekly visit from Assertive 
Outreach staff.  
The Assertive Outreach Teams will get a written summary of the overall results. Each 
Assertive Outreach Team will also receive a summary of anonymous data collected from 
participants being cared for by that team.  
The researchers hope to publish the anonymous results in a journal and in a paper that will be 
kept in the University of Birmingham Library. 
Who is organising and funding the research? 
The study is organised and funded by the University of Birmingham. The Assertive Outreach 
Teams and the researchers are not receiving additional funds to conduct this study. 
Who has reviewed the study? 
All research in the NHS is looked at by an independent group of people, called a Research 
Ethics Committee to protect your safety, rights, wellbeing and dignity. This study has also 
been reviewed by clinical psychologists working at The University of Birmingham. 
Further information and contact details 
If you would like further information or clarification about any aspect of the study please 
contact: 
Victoria Altoft     
Chief Investigator 
School of Psychology  
University of Birmingham 
Edgbaston 
B15 2TT 
Telephone: 0121  4147576 
 
Dr Hermine Graham     Dr Alan Meaden 
Consultant Clinical Psychologist   Consultant Clinical Psychologist 
School of Psychology    208 Monyhull Hall Road 
University of Birmingham    Kings Norton 
Edgbaston     Birmingham 
B15 2TT     B30 3QJ 
Telephone: 0121 4147204   Telephone: 0121 6783400  
 
 
118 
 
     
 
 
 
 
 
APPENDIX 3 
PARTICIPANT CONSENT FORM 
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Version 2     
18/03/2009 
 
CONSENT FORM 
 
Title of Project:  Negative Symptoms in people who experience psychosis,  
and use cannabis 
 
Name of Researcher: Victoria Altoft 
  
Participant Identification for this trial: 
 
1) I confirm that I have read and understand the information    
sheet for the above study. I have had the opportunity to consider  
the information, ask questions and have had these answered  
satisfactorily. 
 
2) I understand that my participation is voluntary and that I am    
free to withdraw at any time before all my answers have been  
collected and analysed, without giving any reason, and without  
my medical care or legal rights being affected. 
 
3) I agree to the my  FACE: Health and Social      
Assessment Scale information that is stored by the Assertive 
Outreach Team to be viewed by the researchers. 
 
4) I understand that my Consultant Psychiatrist and my     
 Assertive Outreach Care-coordinator know that I am  
 participating in the study. 
 
5) I understand that relevant sections of my medical notes    
and data collected during the study, may be looked at  
by individuals from The University of Birmingham, from  
regulatory authorities or from the NHS Trust, where it is 
relevant to my taking part in the research. I give permission 
for these individuals to have access to my records.  
 
6) I agree to take part in the above study.      
 
 
Name of Participant: __________________________________________________________ 
 
Date: __________________    Signature:  ______________________________________ 
         
Name of Person taking consent: _________________________________________________ 
 
Date: ________________     Signature: ______________________________________ 
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APPENDIX 4 
 
DEMOGRAPHIC INFORMATION SHEET 
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APPENDIX 5  
STRUCTURED CLINICAL INTERVIEW FOR  
THE POSITIVE AND NEGATIVE SYNDROME SCALE (PANSS) 
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STRUCTURED CLINICAL INTERVIEW 
FOR THE POSITIVE AND NEGATIVE SYNDROME SCALE 
(SCI ‐PANSS)  
 
Data on LACK OF SPONTANEITY and FLOW OF CONVERSATION, POOR RAPPORT and 
CONCEPTUAL DISORGANISATION. 
 
 
Hi, I’m …..  We’re going to be spending the next 20 or 30 
minutes talking about yourself and your reasons for being 
here. Maybe you can start by telling me something about 
yourself and your background? (Allow at least 5 minutes for a 
non-directive phase serving to establish rapport in the context 
of an overview before proceeding to the specific questions 
listed below.) 
 
 notes 
 
 
Data on ANXIETY.  
 
1. Have you been feeling worried or nervous in the past week?  notes 
     no   
2. Would you say that you’re usually calm and relaxed?   
   
3. What’s been making you feel nervous (worried, uncalm, 
unrelaxed)? 
  
   
4. Just how nervous (worried, etc.) have you been feeling?   
   
5. Have you been shaking at times, or has your heart been 
racing? 
  
   
6. Do you get into a state of panic?   
yes 
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7. Has your sleep, eating or participation in activities been 
affected? 
  
   
 
Data on DELUSIONS (GENERAL) and UNUSUAL THOUGHT CONTENT. 
1. Have things been going well for you?  notes 
   
2. Has anything been bothering you lately?   
   
3. Can you tell me something about your thoughts on life and its 
purpose? 
  
   
4. Do you follow a particular philosophy?   
   
5. Some people tell me they believe in the Devil; what do you 
think? 
  
   
6. Can you read other people’s minds?   
      yes   
7. How does that work?   
   
8. Can others read your mind?   
      yes   
9. How can they do that?   
   
10. Is there any reason that someone would want to read your 
mind? 
  
   
no 
no 
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11. Who controls your thoughts?   
   
 
  
 
 
 
 
 
 
 
Data on SUSPICIOUSNESS/PERSECUTION, PASSIVE/APATHETIC SOCIAL WITHDRAWAL, ACTIVE SOCIAL AVOIDANCE 
and POOR IMPULSE CONTROL. 
1. How do you spend your time these days?  notes 
   
2. Do you prefer to be alone?   
   
3. Do you join in activities with others?   
     no   
4. Why not? … Are you afraid of people or do you dislike 
them? 
  
              If ‘yes’   
5. Can you explain?   
              If ‘yes’   
6. Tell me about it?   
   
7. Do you have many friends?   
           If ‘no’   
8. Just a few? (If ‘yes’ go to Q. 11)   
           If ‘no’   
9. Any? (If ‘no’ ask Why?)   
            If ‘yes’   
yes 
yes 
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10. Why just a few friends?   
   
11. Close friends?   
           If ‘no’   
12. Why not?   
   
13. Do you feel you can trust most people? (If ‘yes’ go to Q15)   
     no   
14. Why not?   
   
15.Are there some people in particular that you don’t trust?  notes 
      yes   
16. Can you tell me who they are? (If ‘no go to Q.22)   
      yes   
17. Why don’t you trust people (or named specific person)?   
(If ‘don’t know’ or ‘don’t want to say’)   
18. Do you have a good reason not to trust?   
   
19. Is there something that … did to you?   
   
20. Perhaps might do to you now?   
              (If ‘yes’)   
21. Can you explain to me?   
   
22. Do you get along well with others?   
     no   
23. What’s the problem?   
yes 
no 
yes 
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24. Do you have a quick temper?   
      yes   
25. Do you get into fights? (if ‘no’ go to Q29)   
      Yes   
26. How do these fights start?   
   
27. Tell me about these fights?   
   
28. How often does this happen?   
   
29. Do you sometimes lose control of yourself?   
   
30. Do you like most people?  notes 
     no   
31. Why not?   
   
32. Are there perhaps some people who don’t like you?   
      yes   
33. For what reason?   
   
34. Do others talk about you behind your back?   
      yes   
35. What do they say about you?   
   
36. Why?   
   
no 
yes 
no 
no 
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37. Does anyone ever spy on you or plot against you? (If ‘no’ go to next 
page) 
  
      yes   
38. Do you sometimes feel in danger? (If ‘no’ go to next page)   
      yes   
39. Would you say your life is in danger? (If ‘no’ go to next page)   
      yes   
40. Is someone thinking of harming you or even perhaps 
thinking of killing you? (If ‘no’ go to next page) 
  
      yes   
41. Have you gone to the Police for help?   
   
 
42. Do you sometimes take matters into your own hands or 
take action on those who might harm you? (If ‘no’ go to next 
page) 
  
      yes   
43. What have you done?   
   
 
Data on HALLUCINATORY BEHAVIOUR and ASSOCIATED  DELUSIONS. 
1. Do you once in a while have strange or unusual 
experiences? 
 notes 
   
2. Sometimes people tell me that they can hear strange noises 
or voices inside their head that others can’t hear. What about 
you? 
  
     no   
3. Do you sometimes receive personal communication from the radio or 
TV? 
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4. From God or the Devil? (If ‘no’ go to Q20)   
      yes   
5. What do you hear?   
   
6. Are these as clear and loud as my voice?   
   
7. How often do you hear these voices (noises, messages, etc)?   
   
8. Does this happen at a particular time of day or all the time?   
                                         Go to Q20   
9. Can you recognise whose voices these are?   
   
10. What do the voices say?   
   
11. Are the voices good or bad?   
   
12. Pleasant or unpleasant?   
   
13. Do the voices interrupt your thinking or your activities?   
   
14. Do they sometimes give you orders or instructions?   
   
15. For example?  notes 
   
16. Do you usually obey these orders (instructions)?   
   
17. What do you make of these voices (or noises): Where do 
they really come from? 
  
  yes  (if voices)  
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18. Why do you have these experiences?   
   
19. Are these normal experiences?   
                                               Go back to Q3   
20. Do ordinary things sometimes look strange or distorted to 
you? 
  
   
21. Do you sometimes have ‘visions’ or see things that others can’t 
see? 
  
      yes   
22. For example?   
   
23. Do these visions seem very real or life-like?   
   
24.How often do you have these experiences?   
   
25. Do you sometimes smell things that are unusual or that 
others don’t smell? 
  
      yes   
26. Please explain.   
   
27. Do you get any strange or unusual sensations from inside your 
body? 
  
      yes   
28. Tell me about this.   
   
no 
no 
no 
Go to  next 
 
Data on SOMATIC CONCERN. 
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1. How have you been feeling in terms of your health?  notes 
                                  if other than ‘good’   
2. What has been troubling you? (Go to Q5)   
   
3. Do you consider yourself to be in top health? (If ‘yes’ go to next 
section) 
  
     no   
4. What has been troubling you?   
   
5. Do you have any medical illness or disease?   
   
6. Has any part of your body been troubling you?   
     no   
7. How is your head? Your heart? Stomach? The rest of your 
body? 
  
                                         
8. Could you explain? (if appropriate)   
   
9. Has your head or body changed in shape or size?   
      yes   
10. Please explain.   
   
11. What is causing these changes?   
if   ‘good’ 
yes 
no 
Go to next section 
 
Data on DEPRESSION. 
1. How has your mood been in the past week: mostly good, mostly 
bad? 
 notes 
                           if ‘mostly good’   
2. Have there been times in the past week that you were feeling sad or   
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unhappy? 
      yes   
3. Is there something in particular that is making you sad?   
   
  notes 
   
4. How often do you feel sad?   
   
5. Just how sad have you been feeling?   
   
6. Have you been crying lately?   
   
7. Has your mood in any way affected your sleep?   
   
8. Has it affected your appetite?   
   
9. Do you participate less in activities on account of your 
mood? 
  
   
10. Have you had any thoughts of harming yourself?   
        
11. Any thoughts about ending your life?   
      yes   
12. Have you attempted suicide?   
   
Go to next section 
no 
 
Go to next section 
Data on GUILT FEELINGS and GRANDIOSITY. 
 same (go 
to Q5) 
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1. If you were to compare yourself to the average person, how 
would you come out: a little better, maybe a little worse, or about 
the same? 
 notes 
              worse   
2. Worse in what ways?   
   
3. Just how do you feel about yourself? (go to Q5)   
   
4. Better in what ways? (go to Q5)   
5. Are you special in some ways?  notes 
      yes   
6. In what ways?   
   
7. Would you consider yourself gifted?   
   
8. Do you have talents or abilities that most people don’t 
have? 
  
      yes   
9. Please explain.   
   
10. Do you have any special powers?   
      yes   
11. What are these?   
   
12. Where do these powers come from?   
   
13. Do you have extrasensory perception (ESP), or can you 
read other people’s minds? 
  
   
  better 
no 
no 
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14. Are you very wealthy?   
      yes   
15. Explain please.   
   
16. Can you be considered to be very bright?   
      yes   
17. Why would you say so?   
   
18. Would you describe yourself as famous?   
      yes   
no 
no 
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no 
go to Q21 
19. Would some people recognise you from TV, radio or the 
newspapers? 
 notes 
             if  ‘yes’   
20. Can you tell me about it?   
   
21. Are you a religious person?   
      yes   
22. Are you close to God?   
      yes   
23. Did God assign you some special role or purpose?   
   
24. Can you be one of God’s messengers or angels?   
      yes   
25. What special powers do you have as God’s messenger 
(angel)? 
  
   
26. Do you perhaps consider yourself to be God?   
no 
no 
no 
no 
no 
 
     
      yes   
27. Do you have some special mission in life?   
      yes   
28. What is your mission?   
   
29. Who assigned you to that mission?   
   
30. Did you ever do something wrong; something you feel bad or guilty 
about? 
  
      yes   
31. Just how much does that bother you now?   
   
32. Do you feel that you deserve punishment for that?   
      yes   
33. What kind of punishment would you deserve?   
   
34. Have you at times thought of punishing yourself?  notes 
      yes   
35. Have you ever acted upon these thoughts?   
no 
no 
no 
go to next 
no 
go to next 
 
Data on DISORIENTATION. 
1. Can you tell me what is today’s date (i.e. the day, the month, the 
year)? 
 notes 
   
2. What is the name of the place you are in now?   
   
3. (If hospitalised) What ward are you on?   
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4. (If hospitalised) What is the address of where you now stay?   
   
5. If someone had to reach you by phone, what number would they 
call? 
  
   
6. What is the name of the doctor who is treating you?   
   
7. (If hospitalised) Can you tell me who else in on the staff and what they 
do? 
  
   
8. Do you know who is now the Prime Minister?   
   
9. Who was the Prime Minister before?   
   
10. Who is the leader of the opposition party?   
 
Data on DIFFICULTY IN ABSTRACT THINKING. 
1. I’m going to now say a pair of words, and I’d like you to 
tell me in what important way they are alike. Lets start for 
example, with the words … see Appendix A. How are they 
alike- what do they have in common? 
 notes 
                                   if correct answer   
2. Good. Now what about….? (Select three other items from 
the similarities list at varying levels of difficulty and based 
upon the interview stage and record the responses. Then go to 
Q4) 
  
(If we use ‘apple & banana’ as the items) The incorrect answer 
will be either CONCRETE (‘they both have skins’ or ‘you can 
eat them’), TANGENTIAL (‘they’re small), or 
IDIOSYNCHRATIC (‘monkeys like them’) – record this in the 
notes section to the left.  
3. Okay, but they’re both… give answer. Now how about … : 
how are these alike? (Select three other items from the 
similarities list at varying levels of difficulty and based upon 
the interview stage and record the responses.) 
  
 if any  other answer 
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4. You’ve probably heard the expression… select proverb from 
Appendix B. What does this really mean? 
  
   
5. What about when people say… select second proverb from 
Appendix B. What do they mean? 
  
   
6. There’s a very old saying… see Appendix B for third 
proverb. What is the deeper meaning of this proverb? (Select 
1 other proverb from the final set in Appendix B) 
  
 
Data on LACK OF JUDGEMENT and INSIGHT. 
          1. How long have you been in the hospital (clinic etc)?  notes 
   
2. Why did you come to the hospital (Clinic, etc)?   
   
3. Do you need to be in the hospital (Clinic, etc)?   
     No   
4. Did you have a problem that needed treatment?   
      Yes   
5. Would you say that you had a psychiatric or mental 
problem? 
 notes 
      Yes   
6. Why… would you say that you had a psychiatric or mental 
problem? 
  
   
7. Can you tell me about it and what it consists of?   
   
8. In your opinion do you need to be taking medicine?   
     no   
yes 
go to Q5 
 no 
go to Q8 
 no 
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9. (If medicated) Why are you then taking medicines? (go to 
Q11) 
OR 
10. (If unmedicated) Why are you still in hospital (clinic, etc)? (go to 
Q12) 
  
   
11. Why?… Does the medicine help you in any way?   
   
12. Do you at this time have any psychiatric or mental 
problems? 
  
   
13. For what reason are you still in the hospital (clinic, etc)?   
                         if reason given   
14. Please explain.   
   
15. Just how serious are these problems?   
   
16. (If hospitalised) Are you ready for discharge from the 
hospital? 
  
   
17. Do you think you will be taking medicine for your problem after 
discharge? 
  
   
18. What are your future plans?   
   
19. What about your longer-range goals? … Well that’s about 
all I have to ask of you now. Are there any questions that you 
might like to ask of me? … Thank you for your co-operation 
  
if no  reason  
            given 
 Appendix A: Items for assessing SIMILARITIES in the evaluation of DIFFICULTY IN ABSTRACT THINKING. 
 
 
 
2‐year assessment 
Baseline/6mth assessment 
1‐year/Discharge/18mth assessment 
Acute ward assessment 
 
 
1. How are a ball and orange alike? 
2. Apple and banana? 
3. Pencil and pen? 
4. Nickel and dime? 
 
2‐year assessment 
Baseline/6mth assessment 
1‐year/Discharge/18mth assessment 
Acute ward assessment 
 
 
5. Table and chair? 
6. Tiger and elephant? 
7. Hat and shirt? 
8. Bus and train? 
 
2‐year assessment 
Baseline/6mth assessment 
1‐year/Discharge/18mth assessment 
Acute ward assessment 
 
 
9. Arm and leg? 
10. Rose and tulip? 
11. Uncle and cousin? 
12. The sun and the moon? 
 
2‐year assessment 
Baseline/6mth assessment 
1‐year/Discharge/18mth assessment 
Acute ward assessment 
 
 
13. Painting and poem? 
14. Hilltop and valley? 
15. Air and water? 
16. Peace and prosperity? 
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 Appendix B: Items for assessing PROVERB INTERPRETATION in the evaluation of DIFFICULTY IN 
ABSTRACT THINKING. 
 
What does the saying mean: 
 
 
2‐year assessment 
Baseline/6mth assessment 
1‐year/Discharge/18mth assessment 
Acute ward assessment 
 
 
1. “Plain as the nose on you face”? 
2. “Carrying a chip on your shoulder”? 
3. “Two heads are better than one”? 
4. “Two many cooks spoil the broth”? 
 
2‐year assessment 
Baseline/6mth assessment 
1‐year/Discharge/18mth assessment 
Acute ward assessment 
 
 
5. “Don’t judge a book by its cover”? 
6. “One man’s food is another man’s poison”? 
7. “All that glitters is not gold”? 
8. “Don’t cross the bridge until you come to it”? 
 
2‐year assessment 
Baseline/6mth assessment 
1‐year/Discharge/18mth assessment 
Acute ward assessment 
 
 
9. “What’s good for the goose is good for the gander”? 
10. “The grass always looks greener on the other side”? 
11. “Don’t keep all your eggs in one basket”? 
12. “One swallow does not make a Summer”? 
 
2‐year assessment 
Baseline/6mth assessment 
1‐year/Discharge/18mth assessment 
Acute ward assessment 
 
 
13. “A stitch in time saves nine”? 
14. “A rolling stone gathers no moss”? 
15. “The acorn never falls far from the tree”? 
16. “People who live in glass houses should not throw 
stones at others”? 
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 Panss Rating Form    Name          Date  __ 
   
absent  minimal  mild  moderate 
moderate 
severe 
severe  extreme 
P1  Delusions  1  2  3  4  5  6  7 
P2  Conceptual disorganisation  1  2  3  4  5  6  7 
P3  Hallucinatory behaviour  1  2  3  4  5  6  7 
P4  Excitement  1  2  3  4  5  6  7 
P5  Grandiosity  1  2  3  4  5  6  7 
P6  Suspiciousness/persecution  1  2  3  4  5  6  7 
P7  Hostility  1  2  3  4  5  6  7 
N1  Blunted affect  1  2  3  4  5  6  7 
N2  Emotional withdrawal  1  2  3  4  5  6  7 
N3  Poor rapport  1  2  3  4  5  6  7 
N4 
Passive/apathetic social 
withdrawal 
1  2  3  4  5  6  7 
N5  Difficulty in abstract thinking  1  2  3  4  5  6  7 
N6 
Lack of spontaneity & flow of 
conversation 
1  2  3  4  5  6  7 
N7  Stereotyped thinking  1  2  3  4  5  6  7 
G1  Somatic concern  1  2  3  4  5  6  7 
G2  Anxiety  1  2  3  4  5  6  7 
G3  Guilt feelings  1  2  3  4  5  6  7 
G4  Tension  1  2  3  4  5  6  7 
G5  Mannerisms & posturing  1  2  3  4  5  6  7 
G6  Depression  1  2  3  4  5  6  7 
G7  Motor retardation  1  2  3  4  5  6  7 
G8  Uncooperativeness  1  2  3  4  5  6  7 
G9  Unusual thought content  1  2  3  4  5  6  7 
G10  Disorientation  1  2  3  4  5  6  7 
G11  Poor attention  1  2  3  4  5  6  7 
G12  Lack of judgement & insight  1  2  3  4  5  6  7 
G13  Disturbance of volition  1  2  3  4  5  6  7 
G14  Poor impulse control  1  2  3  4  5  6  7 
G15  Preoccupation  1  2  3  4  5  6  7 
G16  Active social avoidance  1  2  3  4  5  6  7 
 
142 
 
  
 
 
 
 
APPENDIX 6 
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APPENDIX 7 
SECTION B OF THE MAUDSLEY ADDICTION PROFILE (MAP) 
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APPENDIX 8 
SEVERITY OF DEPENDENCE SCALE (SDS) 
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